

Recurrent evolution of ligand-binding domain multiplicity fine-tunes TGF β signaling in vertebrates

Petra Knaus

petra.knaus@fu-berlin.de

Freie Universitaet Berlin <https://orcid.org/0000-0003-2492-1667>

Jerome Jatzlau

Freie universitaet Berlin

Michael trumpp

Freie Universität Berlin

Julia Kühlwein

Freie Universität Berlin

Leon Obendorf

Freie Universität Berlin

Yao Le

National university Singapore

Heiner Kuhl

Leibnitz Institute

Marco Preussner

FU Berlin <https://orcid.org/0000-0001-5155-0844>

Paul Mendez

Freie Universität Berlin

Hendrik Burkert

Freie Universität Berlin

Wiktor Burdzinski

Freie Universität Berlin

Stefan Mundlos

Max Planck Institute for Molecular Genetics <https://orcid.org/0000-0002-9788-3166>

Christoph Winkler

University of Singapore <https://orcid.org/0000-0003-4688-6241>

Matthias Stöck

Leibniz Institute of Freshwater Ecology and Inland Fisheries (IGB) <https://orcid.org/0000-0003-4888-8371>

Biological Sciences - Article

Keywords:

Posted Date: January 16th, 2026

DOI: <https://doi.org/10.21203/rs.3.rs-8406929/v1>

License:   This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Additional Declarations: There is **NO** Competing Interest.

1 Recurrent evolution of ligand-binding domain
2 multiplicity fine-tunes TGF β signaling in vertebrates
3

4 Jerome Jatzlau^{1,*},[✉], Michael Trumpp^{1,2,*}, Julia Kühlwein¹, Leon Obendorf^{1,2}, Yao Le⁶,
5 Heiner Kuhl^{5,7}, Marco Preussner¹, Paul Mendez¹, Hendrik Burkert¹, Wiktor
6 Burdzinski^{1,3}, Stefan Mundlos⁸, Christoph Winkler⁶, Matthias Stöck⁵, Petra Knaus^{1,3},[✉]

7
8 ¹ Freie Universität Berlin, Institute of Chemistry and Biochemistry - Biochemistry, Berlin, Germany.

9 ² International Max Planck Research School for Biology and Computation, Berlin, Germany

10 ³ Berlin-Brandenburg School for Regenerative Therapies (BSRT), Berlin, Germany.

11 ⁴ Leibniz-Forschungsinstitut für Molekulare Pharmakologie, Berlin, Germany.

12 ⁵ Department of Fish Biology, Fisheries and Aquaculture, Leibniz Institute of Freshwater Ecology and
13 Inland Fisheries, Berlin, Germany.

14 ⁶ Department of Biological Sciences and Centre for Bioimaging Sciences, National University of
15 Singapore, Singapore, Singapore.

16 ⁷ Ecotoxicological Laboratory, German Environment Agency (UBA), Berlin, Germany.

17 ⁸ Max Planck Institute for Molecular Genetics, Berlin, Germany.

18 [✉] Corresponding author

19 * Equal contributing authors

20

21 Abstract

22

23 From sponges to mammals, TGF β -signaling has evolved as one of the key pathways
24 governing body plans, organ and cell type differentiations as well as homeostatic balance. The
25 extensive conservation of the receptor core architecture across metazoans reflects strong
26 evolutionary constraints, consistent with the severe developmental phenotypes caused by
27 TGF β receptor mutations in humans. Here, we identify unexpected evolutionary divergence
28 within a key receptor structure: 12 independent multiplications of the ligand-binding domain
29 across three receptor classes (ACVR1, BMPR2, TGFBR2) in a diverse set of vertebrate
30 lineages, including fish, amphibians, birds, and mammals. These ligand binding domain
31 duplications indicate structural and functional plasticity of TGF β receptors arising from domain-
32 level innovation, a feature that has remained unnoticed in established model organisms
33 including zebrafish, the African clawed frog, and chicken. Two principal effects emerged. First,
34 recently diverged lineages display strong conservation of the membrane-proximal ligand
35 binding domain (LBD) relative to the membrane-distal LBD, including the ligand-interacting
36 residues. In species such as chicken and salmon, this pattern is associated with enhanced
37 ligand binding. Second, more ancient lineages, such as zebrafish, exhibit elevated evolutionary
38 rates in the membrane-distal LBD, corresponding to the acquisition of an inhibitory function.
39 Our findings reveal LBD multimerization as a recurring, lineage-independent broader
40 mechanism to diversify or fine-tune TGF β -signaling. This adds a novel regulatory dimension
41 to one of the best-examined conserved and essential pathways in metazoan biology.

42

43 Introduction

44

45 Signaling through ligand-binding receptors has been a cornerstone of multicellular life since
46 the early evolution of metazoans¹. Multiplication of single exon-coded domains shaped the
47 extracellular architectures of many growth factor receptors. Some, such as EGF-, FGF-, and
48 VEGF receptors, contain repeated ligand-binding domains (LBDs), yet the number and
49 arrangement of these repeats have remained conserved from early metazoans to vertebrates²⁻
50 ⁵. By contrast, other key ligand-binding receptors such as those of the TGF β receptor family
51 have been supposed to contain only a single LBD, conserved from invertebrates to mammals.
52 Remarkably, we found an exception in this otherwise highly conserved pathway: in medaka
53 (*Oryzias latipes*), a single exon encoding the ligand-binding domain in *ACVR1* underwent
54 triplication, producing a receptor with three tandem LBDs⁶.

55 The TGF β -receptor family, comprising TGF β and bone morphogenetic protein (BMP)
56 receptors, represents a highly conserved signaling system, essential for regulating
57 developmental and homeostatic processes across all vertebrates⁷. Their roles span from
58 orchestrating early embryonic tissue formation to fine-tuning cellular identities across diverse
59 cell lineages^{8,9}. These receptors share a characteristic organization, an extracellular LBD
60 followed by a transmembrane (TM) and an intracellular kinase domain (KD)^{10,11}, that is
61 preserved from invertebrates to vertebrates.

62 Following two rounds of whole-genome duplication (WGD) events, the number of TGF β
63 receptor genes expanded from five in invertebrates¹² to thirteen in vertebrates¹³, of which
64 twelve are retained in mammals, including five type II and seven type I receptors¹⁴. This
65 expanded receptor repertoire co-evolved with more than thirty TGF β ligand family members,
66 forming highly specific ligand–receptor pairs¹⁴. Upon ligand binding to their high-affinity
67 receptors, a tetrameric complex of two type I and two type II receptors assembles, enabling
68 transphosphorylation and activation of the type I receptor kinase by a constitutively active type
69 II kinase. Activated type I receptors phosphorylate intracellular mediators, most commonly
70 SMAD transcription factors, which regulate the expression of TGF β /BMP target genes in a cell
71 type- and context-dependent manner to control key developmental decisions⁸.

72 In this study we investigated whether LBD multiplications within the TGF β receptor family are
73 more widespread as previously recognized and how such structural innovations affect receptor
74 signaling. Through a comprehensive analysis across vertebrate genomes, we identified 12
75 independent cases of convergent LBD multiplication in three TGF β receptor genes, spanning
76 a broad phylogenetic range from fish to mammals. These events were detected in multiple
77 species, including elephant-nose fish, carps, clawed frogs, chicken and horses, highlighting
78 that LBD multimerization is a recurrent evolutionary phenomenon across vertebrate lineages.
79 Our findings reveal that these can substantially modulate receptor signaling properties. Thus,
80 LBD multiplication represents a previously unknown mode of molecular innovation within the
81 highly conserved TGF β signaling system, adding a new layer of complexity and regulatory
82 potential to this essential developmental pathway.

83

84

85

86 Results

87

88 1. WGD-independent LBD multiplication events in TGF β receptors in 89 vertebrate evolution

90

91 Previously, we identified and verified that the medaka *ACVR1* paralogs, derived from teleost-
92 specific whole genome duplication, differ in their number of LBDs⁶. Whereas the medaka
93 *ACVR1* carries three LBDs, the *ACVR1L* gene encodes for a BMP type I receptor with only 1
94 LBD. In contrast, zebrafish (*Danio rerio*) has lost the *ACVR1* gene and retained only *ACVR1L*
95 with 1 LBD. To trace the origin of the *ACVR1* LBD triplication, we compared available genome
96 and transcriptome data across various ray-finned fish (Actinopterygii) lineages, supplementing
97 missing data with RNA sequencing of heart tissues from selected representatives of individual
98 families (**Fig. 1**). We found that an initial duplication of the *ACVR1* LBD occurred in the early
99 ancestors of Osteoglossocephalai, followed by a secondary triplication event common to all
100 Clupeocephala. Interestingly, individual LBDs were subsequently lost within herrings,
101 anchovies and shads (Clupeoidei), and the entire *ACVR1* gene was lost in all carp-like fishes
102 (Cyprinoidei). We next asked whether LBD multiplication is specific to the *ACVR1* locus, or if
103 it is a common feature across all teleost genomes following evolutionary adaptation after the
104 teleost whole genome duplication event¹⁵. Surprisingly, we found an LBD triplication event in
105 the *ACVR1* paralog *ACVR1L*, which is unique to the bonytongues (Osteoglossidae). We
106 uncovered six additional LBD multiplication events in the type II receptor genes *BMP2* and
107 *TGFBR2*, indicating a broader pattern beyond the *ACVR1* locus. Notably, the *BMP2* gene
108 underwent LBD triplication twice, once within the bichirs (Polypteridae) and once the
109 featherbacks and knifefishes (Notopteroidei). These events appear to be independent of
110 *BMP2* paralogy, as Polypteridae diverged before the teleost whole genome duplication. The
111 *TGFBR2* locus underwent four independent LBD multiplication events in Clupeoidei,
112 Cyprinoidei, pikes and mudminnows (Esociformes), and salmonids (Salmoninae). While the
113 carp-specific *TGFBR2* LBD duplication preceded the carp-specific whole genome duplication
114 (WGD) (**Supp Fig. 3A**), the *TGFBR2* LBD multimerization in Salmoninae occurred after the
115 salmon-specific WGD. Finally, we extended our analysis to all jawed vertebrates
116 (Gnathostomata) (**Fig. 2**) to test whether TGF β -superfamily receptor LBD multiplication
117 depends on preceding WGD. We identified four additional *TGFBR2* LBD multiplication events:
118 one in the *TGFBR2* paralog *TGFBR2L* within the african lungfish (Protopteridae), and three in
119 *TGFBR2* within amphibians (Amphibia), chicken (*Gallus*)¹⁶, and odd-toed hoofed mammals
120 (Perissodactyla). Collectively, we identified 12 convergent LBD multiplication events across
121 three TGF β -family receptor genes, *ACVR1/ACVR1L*, *BMP2*, and *TGFBR2/TGFBR2L*, in
122 species that had undergone WGD and retained a backup paralog (e.g., *ACVR1* in all teleosts,
123 or *TGFBR2* in Salmoninae). However, we also observed LBD multiplication in species with
124 only a single gene copy, such as *BMP2* in Polypteridae and *TGFBR2* in Perissodactyla,
125 suggesting that WGD is not a prerequisite for LBD multimerization. Interestingly, type I receptor

126 LBDs are encoded by a single exon, whereas type II receptor LBDs are split across two exons,
127 highlighting that, in the case of *BMPR2* and *TGFBR2*, duplication of an entire exon pair was
128 required (**Supp Fig. 4A**). Since the *TGFBR2* locus exhibited the highest number of LBD
129 duplication events, we next investigated whether repetitive elements flanking exons 2 and 3 of
130 *TGFBR2* are conserved across species, potentially facilitating repeated independent
131 duplications. Whereas in the zebrafish *Tgfr2a* locus, retroelement derived GT-rich sequences
132 are framing the duplicated exon pair, these or other repetitive sequences are absent in the
133 chicken (*Gallus gallus*) and horse (*Equus caballus*) *TGFBR2* loci at duplication sites (**Supp**
134 **Fig. 4B**). The duplication sizes range widely, from ≥ 2.1 kb in zebrafish to ≥ 18.7 kb in horse,
135 indicating that these exon-pair duplications arose through separate genetic events rather than
136 from a shared ancestral duplication (**Supp Fig. 4B**).

137

138 2. The membrane-proximal LBD conveys ligand binding and signaling 139 competences in multimerized elephant-nose fish gnBmpr2a 140

140

141 To assess the molecular function of convergently multimerized LBDs, we first analysed the
142 sequence conservation among 3 LBDs within individual *BMPR2* proteins of the Notopteroidei
143 and Polypteridae lineages (**Fig. 3A, Supp. Fig. 1B**). In both groups, the LBDs exhibited
144 intermediate levels of sequence identity (50-70%) relative to the membrane-proximal LBD
145 (LBDⁱⁿ), suggesting partial functional divergence within the repeats (**Fig. 3A**). *BMPR2* functions
146 as a type II receptor for a wide range of BMP and Activin ligands^{17,18}. Whereas BMP binding
147 to *BMPR2*-containing receptor complexes requires the presence of a high affinity type I
148 receptor, *BMPR2* can directly bind Activin A through a specific set of hydrogen bonds and
149 hydrophobic interactions primarily involving residues located between fingers 2 and 3 (**Fig. 3B,**
150 **C**)¹⁹.

151 To determine the conservation of these critical interaction sites, we compared the *BMPR2* LBD
152 residues involved in ligand binding across the 3 domains. In both lineages, the inner LBD
153 showed the highest degree of sequence conservation with human *BMPR2*, particularly at
154 residues forming the Activin-specific binding interface (**Fig. 3C**). Interestingly, the inner LBDs,
155 of Notopteroidei species retained 85% of the key residues involved in A-loop contacts in finger
156 2, while Polypteridae retained 69% (**Fig. 3C, D**). Consistent with this, members of the
157 Notopteroidei also exhibited minimal loss of conserved interaction-mediating residues on finger
158 3, consistent with a maintained or partially preserved capacity of Activin binding in LBDⁱⁿ (**Fig.**
159 **3D, Supp. Fig. 5A**).

160 To explore the functional impact of LBD triplication in *BMPR2* receptors from Notopteroidei,
161 we performed computational protein-protein docking using the Rosetta Commons suite²⁰.
162 Docking simulations were conducted using the triplicated LBD of *BMPR2a* from elephant-nose
163 fish (*Gnathonemus petersii*; member of the Notopteroidei), and human Activin A as the ligand
164 (**Fig. 3E, Supp. Fig. 5B**). Additionally, lineage-specific docking analyses were performed using
165 the appropriate Activin A orthologs for both Notopteroidei and Polypteridae species (**Supp.**
166 **Fig. 5E-G**). Consistent with the LBD conservation analysis (**Fig. 3A-C**), the inner LBD showed
167 the lowest predicted interface energy, indicating the highest ligand-binding affinity (**Fig. 3E**).
168 To experimentally test the functionality of the individual LBDs, we generated expression
169 constructs of elephant-nose fish *BMPR2a*, including full-length receptors, deletion mutants
170 containing only one or two LBD (LBD^{mid-in}). Binding of fluorescently-labelled human Activin A-

171 Cy5 was assayed using ligand surface binding assay (LSBA, **Fig. 3F**; **Supp. Fig. 5C,6**)²¹, and
172 downstream signaling was quantified via a CAGA₁₂-driven dual luciferase assay, which reports
173 SMAD2/3 activity (**Fig. 3G**; **Supp. Fig. 5D**).

174 In agreement with the docking predictions, only the inner, membrane-proximal LBD bound
175 Activin A with high affinity. Neither the outer, nor the middle LBD alone showed detectable
176 binding, while LBDⁱⁿ and LBD^{mid-in} exhibited comparable binding to the full-length receptor (**Fig.**
177 **3F**). This binding pattern was mirrored in the functional signaling output: constructs containing
178 only the outer or middle LBD showed minimal SMAD2/3 activation, whereas LBDⁱⁿ displayed
179 the highest signaling competence (**Fig. 3G**). Notably, deletion of the outer and middle LBDs
180 enhanced signaling efficiency, indicating that these LBDs are functional but act repressively,
181 whereas only the membrane-proximal inner LBD contributes positively to Activin A
182 responsiveness in the LBD triplicated receptor (**Fig. 3G**).

183

184 3. Multimerized TGFBR2 LBDs follow divergent evolutionary adaptations to 185 fine-tune signaling 186

187 Next, we examined the TGFBR2 gene, which independently acquired LBD multiplications in
188 seven distinct lineages, followed by additional expansions in salmonids and amphibians, as
189 seen in atlantic salmon (*Salmo salar*; 3 LBDs) and lake trout (*Salvelinus namaycush*; 5 LBDs),
190 gaboon caecilian (*Geotrypetes seraphini*; 3 LBDs), and african clawed frog (*Xenopus laevis*; 3
191 LBDs) (**Fig. 1,2**). To predict the molecular function of the multimerized LBD receptors, we first
192 compared the LBD sequence homology within one protein (**Fig. 4A**). We observed that the
193 degree of conservation varied among the seven families. While the carp (*Cyprinus carpio*) and
194 clawed frog TGFBR2 LBDs showed the lowest conservation (25–50%) relative to the
195 membrane-proximal LBD (LBDⁱⁿ), pike (*Esox lucius*) and herring (*Clupea harengus*) exhibited
196 intermediate conservation (50–90%), and the salmon, chicken, and horse displayed high
197 conservation levels (90–100%). (**Fig. 4A**). TGFBR2 is known for its high affinity binding to
198 TGFβ-ligands via polar and hydrophobic interactions of residues mainly residing in finger 1 of
199 the LBD (**Fig. 4B, C**)²². When comparing the amino acids, which form the interaction epitope
200 for human TGFβ1 within TGFBR2, these are highly conserved in the LBDⁱⁿ domain of all tested
201 species, whereas the middle or outer LBD domains show a lower degree of conservation (**Fig.**
202 **4C, Supp. Fig 7**). Interestingly, consistent with its overall low degree of conservation, the
203 zebrafish *Tgfr2a* LBD^{out} shows no conserved TGFβ1-binding amino acid residues (**Fig. 4C,**
204 **D**). In contrast, the chicken LBDs exhibit 98% overall similarity and share an identical TGFβ1-
205 binding epitope (**Fig. 4C, D**). Lastly, the horse and tapir LBD^{out} show a high level of overall
206 conservation (93.1%, 96%), with three or one amino acid substitutions within the TGFβ1-
207 binding epitope, respectively (**Fig. 4C, D; Supp. Fig 7**). In contrast, to the varying degree of
208 conservation on the side of the LBD interface, all TGFβ1 ligand orthologs show a complete
209 conservation of amino acids forming the receptor interacting interface (**Supp. Fig 7**). Finally,
210 to evaluate whether the extent of duplicated LBD sequence divergence corresponds to the
211 evolutionary time separating each lineage, we calculated molecular clocks using orthologous
212 LBD domains. The resulting lineage-specific clocks indicated that the LBD duplications in
213 horse, chicken, and salmon evolved at rates consistent with their respective orthologous LBDs,
214 indicating that these domains remain highly conserved under a clock-like model of evolution.
215 However, the zebrafish LBD duplication strongly deviated from this pattern, exhibiting an
216 exceptionally high substitution rate, far exceeding that of the clade-specific (otomorpha) LBD
217 molecular clock, indicative of accelerated evolution (**Supp. Fig 8**).

218 To functionally predict the effect of TGFBR2 LBD duplication on ligand binding capabilities we
219 again performed protein-protein docking studies (**Fig. 5A**) using human TGF β 1 and the
220 respective animal ortholog TGF β 1, which exhibit a high degree of conservation (**Fig. 5, Supp.**
221 **Fig. 9,10,11**). Furthermore, we cloned zebrafish, carp, clawed frog, chicken and horse
222 TGFBR2 expression constructs, and generated single LBD mutants, to separately test the
223 functionality of individual LBDs. Using fluorescently labeled human TGF β 1-SiRd12, we
224 performed LSBA²¹ to verify the predicted docking data (**Fig. 5B**) and tested the downstream
225 signaling response using the SMAD2/3-sensitive CAGA₁₂-dual luciferase assay (**Fig. 5C**). In
226 line with the low degree of LBD conservation in both zebrafish and carp Tgfbr2a, the LBD^{out}
227 exhibits almost no TGF β 1 binding, whereas the LBDⁱⁿ domain is capable of TGF β 1 binding
228 and transmitting signals (**Fig. 5D-F, Supp. Fig. 9A-C, 12, 13**). Strikingly, only in the zebrafish
229 dTgfbr2a the presence of the LBD^{out} is inhibitory on TGF β 1-binding to the LBDⁱⁿ, as seen by
230 diminished ligand binding in the LSBA (**Fig. 5E, Supp. Fig. 12**), and reduced SMAD2/3 activity
231 as seen in the reporter gene assay (**Fig. 5F**).

232 Similarly, in horse and frog TGFBR2 orthologs, the membrane-proximal domain LBDⁱⁿ shows
233 the highest predicted and experimentally confirmed binding to TGF β 1, while the outer domain
234 (LBD^{out}) exhibits reduced or no binding and lacks signaling competence. Importantly, the
235 presence of the LBD^{out} does not impair binding or signaling function of the full length TGFBR2
236 for either species (**Fig. 5G-I, Supp. Fig. 9D-F, 14, 15**).

237 In contrast, chicken TGFBR2 shows a different pattern. Both LBDⁱⁿ and LBD^{out} share a
238 conserved TGF β 1 binding epitope and 98% sequence identity, resulting in similar predicted
239 and measured TGF β 1 binding. Each domain alone is sufficient to support efficient ligand
240 binding and downstream signaling (**Fig. 5J-L, Supp. Fig. 16**). Interestingly, the native chicken
241 receptor containing both LBDs binds TGF β 1 more strongly than either single domain receptor
242 although signaling output remains comparable regardless of the number of LBDs (**Fig. 5K-L**).

243 To model the functional impact of a recent, fully conserved LBD duplication, we engineered a
244 synthetic human TGFBR2 variant with two identical LBDs and assessed its ability to bind
245 human TGF β 1. Consistent with the chicken receptor, LBD duplication significantly enhanced
246 ligand binding (**Fig. 6A-B, Supp. Fig. 17**). Whereas CAGA₁₂-luc activity after 24 hours was
247 comparable for both TGFBR2 variants (**Fig. 6C**), short term activation of SMAD2 was reduced
248 in the presence of TGFBR2 2 LBD compared to TGFBR2 expression (**Fig. 6D**). Collectively,
249 this highlights that 2 LBD TGFBR2 receptors remain functional but limit the downstream SMAD
250 activation through excessive ligand binding (**Fig. 6E**).

251 These findings suggest that LBD duplication in TGFBR2 is a recurrent evolutionary mechanism
252 capable of fine-tuning ligand binding without compromising signaling output, thereby offering
253 a potential selective advantage under specific physiological or developmental contexts.

254

255 4. LBD duplication generates a low-signaling dTgfbr2a variant with tissue- 256 specific roles in zebrafish 257

258 Notably, TGFBR2 two-LBD variants from different species exhibited different signaling
259 capabilities, which raises the question how these integrate into the critical fine-tuning of
260 balanced BMP and TGF β signaling in the respective species. To answer this, we analyzed
261 publicly available RNA-seq datasets to screen for tissue-specific expression patterns in
262 chicken, horse and zebrafish, which were characterized by different TGFBR2 variants. In both
263 chicken and horse, the TGFBR2 two-LBD variant was highly expressed in the cardiovascular
264 and reproductive systems (**Supp. Fig. 18B**). Interestingly, the high degree of amino acid

265 homology between both LBDs is equally reflected in the coding sequence of exon 3 and exon
266 3' for both TGFBR2 ortholog variants (**Supp. Fig. 18A**). Exon duplication events have been
267 associated with alternative splicing in multiple gene families, e.g., immunoglobulin superfamily
268 members²³ and tropomyosin²⁴. Indeed, in both chicken and horse, we observed single LBD
269 variants due to alternative splicing but at a marginal rate, indicating that the TGFBR2 two-LBD
270 variant is the predominant receptor (**Supp. Fig. 18B-C**).

271 Similarly, zebrafish express only a two-LBD variant of dTgfr2a and do not exhibit alternative
272 splicing at this locus. However, unlike chicken and horse, zebrafish possess a second paralog,
273 Tgfr2b, which encodes a receptor variant containing a single LBD (**Fig. 7A**). To compare the
274 functional properties of these paralogs, we assessed their ligand-binding affinity and signaling
275 capacity. The LBD of dTgfr2b displayed a modestly higher affinity for TGF β 1 relative to the
276 inner LBD of dTgfr2a (**Fig. 7B**). Notably, dTgfr2b also showed markedly increased ligand
277 sequestration at the cell surface, likely attributable to the inhibitory effect of the outer LBD in
278 dTgfr2a (**Fig. 7C**). This was reflected in reduced downstream signaling competence of
279 dTgfr2a vs. dTgfr2b, suggesting potential for fine tuning TGF β signaling by dTgfr2a
280 compared to dTgfr2b, indicating that the two paralogs may enable nuanced regulation of
281 TGF β signaling in zebrafish (**Fig. 7D**).

282 To explore potential tissue-specific functions of the two zebrafish paralogs, we analyzed
283 publicly available single-cell RNA-sequencing data from developing zebrafish embryos. In
284 contrast to chicken and horse, where only the two-LBD variant is present, the single-LBD
285 dTgfr2b paralog was broadly expressed across all tissues (**Fig. 7E**). By contrast, the two-LBD
286 dTgfr2a paralog displayed selective enrichment in the intermediate mesoderm and
287 hematopoietic lineages, with its expression increasing relative to dTgfr2b during development
288 (**Fig. 7F-G**).

289 Comparative transcriptomic profiling of cells expressing either Tgfr2 paralog revealed largely
290 non-overlapping gene expression signatures, suggesting distinct biological roles (**Fig. 7H**).
291 Gene Ontology (GO) enrichment analysis revealed that genes specifically upregulated in
292 dTgfr2a⁺ cells were predominantly associated with cytoskeletal remodeling, small GTPase
293 signaling and migration, particularly within immune and cardiovascular contexts (**Fig. 7I**).
294 Given the well-established role of TGF β -signaling in driving cellular plasticity through epithelial-
295 to-mesenchymal-transition (EMT)²⁵⁻²⁸, we next interrogated the expression of canonical EMT
296 transcription factors. Intriguingly, EMT drivers such as Zeb1, Snai, Slug and Twist were
297 markedly enriched in dTgfr2b⁺ cells (**Fig. 7J**), consistent with its higher signaling competence
298 relative to dTgfr2a (**Fig. 7D**).

299 To validate these differences *in vivo*, we transiently expressed each receptor in developing
300 zebrafish embryos. Expression of dTgfr2b robustly induced phenotypes associated with
301 imbalanced TGF β /BMP-signaling^{29,30}, including increased incidence of cyclopia and
302 ventralization compared to dTgfr2a (**Fig. 7K, Supp. Fig. 19**). Notably, deletion of the outer
303 LBD in dTgfr2a restored signaling activity, phenocopying the higher incidences of
304 ventralization and cyclopia observed with dTgfr2b, and indicating a structural basis for
305 reduced signaling capacity of dTgfr2a (**Fig. 7K**). Conversely, the isolated expression of
306 dTgfr2a LBD^{out} enhanced cyclopia incidence relative to full-length dTgfr2a, but not
307 ventralization. Overall, the elevated ventralization observed *in vivo* is consistent with the higher
308 signaling output measured *in vitro*, suggesting that increased dTgfr2 signaling capability
309 contributes to the ventralizing effect (**Fig. 7D, K**).

310 Together, these findings reveal that LBD duplication in paralogous TGFBR2 receptors can
311 drive neofunctionalization, yielding a receptor variant with attenuated signaling capacity. This
312 structural innovation likely enables tissue-specific modulation of TGF β -signaling output,

313 offering a previously unrecognized mechanism by which vertebrates can diversify and fine-
314 tune key developmental and homeostatic pathways.

315 Discussion

316

317 In this study, we identify a striking evolutionary innovation: independent duplication of ligand-
318 binding domains across three receptor classes (*ACVR1*, *BMP2*, *TGFBR2*) in at least 12
319 vertebrate lineages. Our findings reveal that LBD multiplication serves as an evolutionary
320 platform for modulating TGF β -signaling at two distinct levels, by influencing ligand-binding
321 capacity (e.g., chicken) or signal transmission efficacy (e.g., zebrafish). Moreover, we uncover
322 recurrent instances of secondary LBD trimerization, notably within amphibians and salmonids,
323 suggesting a sustained selective pressure for structural innovations in receptor design. These
324 repeated, lineage specific adaptations point to a broader strategy by which vertebrates fine-
325 tune pathway responsiveness through domain architecture. Given the association of TGF β
326 receptor mutations with numerous human developmental disorders³¹⁻³³, our findings
327 underscore the evolutionary constraints on receptor core architecture, while simultaneously
328 revealing unexpected structural plasticity through domain-level innovation.

329 The evolutionary roots of the TGF β -receptors trace back to early metazoans such as sponges
330 and placozoans, which encoded a minimal complement of two type I and one type II receptor
331 genes¹⁴. With the emergence of bilateral symmetry, the TGF β ligand repertoire expanded in
332 parallel, reflecting the increasing demand for finely tuned BMP and TGF β signaling during axis
333 specification and early morphogenesis³⁴. By contrast, vertebrates exhibit a markedly expanded
334 TGF β receptor repertoire, reflecting two rounds of whole-genome duplications, with additional
335 lineage-specific duplications in teleosts, *Xenopus laevis*³⁵⁻³⁷ and more recently in carps and
336 salmonids^{14,38,39}. This expansion supports the complex and context-dependent roles of TGF β
337 family ligands in vertebrate development, where they direct tissue specification, cell
338 movement, and patterning along dorsal–ventral and anterior–posterior axes⁷.

339 Despite this diversification, vertebrate genomes encode more ligands than receptors, making
340 signaling specificity heavily reliant on selective ligand expression and combinatorial assembly
341 of tetrameric receptor complexes^{14,34}. Tight regulatory control is achieved through multiple
342 mechanisms, including soluble antagonists, co-receptors, transcriptional modulators, and both
343 post-translational and epigenetic modifications⁴⁰. The evolutionary significance of maintaining
344 these precise interactions is underscored by the strong sequence conservation observed in
345 co-evolved ligand-receptor pairs⁴¹.

346 Recurrent vertebrate WGDs generated additional TGF β receptor paralogs, facilitating the
347 evolutionary refinement of TGF β signaling. Retention and divergence of paralogous receptor
348 genes allowed one copy to evolve neofunctionalized or modular domain, while the other
349 maintained a canonical receptor form^{41,42}. This is exemplified by multiple teleost species,
350 where Y-linked *AMHR2* paralogs evolved truncated LBDs and ligand-independent activity, co-
351 opting as sex-determining factors across diverse lineages, including sharks, catfishes, percids,
352 the alligator pipefishes and the common seadragon⁴³⁻⁴⁶.

353 Here we showed that twelve independent LBD expansions across *ACVR1*, *BMP2*, and
354 *TGFBR2* arose at different time points in vertebrate evolution. These events demonstrate that
355 ligand-binding domain multimerization has repeatedly evolved as a novel layer of refining
356 TGF β receptor function. Intriguingly, domain multimerization is not limited to vertebrates.
357 Independent extracellular domain duplications in ancestral *TGFBR2* orthologs have been
358 described in invertebrates such as sponges and oysters^{47,48}, indicating that LBD duplication is
359 an evolutionarily widespread strategy, independent of WGDs.

360 The initial functional advantage of LBD duplication likely relates to the context-specific
361 assembly of tetrameric TGF β -receptor complexes⁴⁹. While a second LBD does not alter
362 receptor stoichiometry per se, it could enhance ligand capture, especially for high affinity
363 receptors such as TGFBR2, in tissues with low ligand availability or restricted diffusion. For
364 instance, duplicated LBDs in chicken, tapir and salmon TGFBR2s are nearly identical,
365 potentially facilitating enhanced ligand avidity or interaction with ECM-bound latent ligands,
366 analogous to the role of the co-receptor endoglin in BMP9 signaling^{50,51}. In these species the
367 duplicated LBDs show low amino-acid substitution rates, in line with the clade-specific
368 molecular clock, indicating that they are under strong evolutionary constraint and remain highly
369 conserved. This is reflected by enhanced TGF β 1 binding of a synthetic human 2 LBD TGFBR2.
370 Whereas, this receptor exhibits limited SMAD activation, likely due to high ligand
371 sequestration, it remains an open question how 2 LBD receptors integrate into the native
372 receptor complex compositions, including tetrameric complex stoichiometries and modulatory
373 co-receptors. Notably, in lineages such as chicken and horse, alternative splicing can generate
374 receptor variants that selectively include or exclude individual LBDs, suggesting that both
375 duplicated domains remain functionally relevant and may be differentially deployed depending
376 on cellular context.

377 This contrasts with zebrafish, where the duplicated outer LBD shows markedly higher amino-
378 acid substitution rate, indicating relaxed constraint and suggesting that the domain is drifting
379 or diversifying rather than being maintained for interchangeable function. Such relaxed
380 constraint is likely enabled by the presence of the paralogous receptor (Tgfbr2b) that provides
381 functional redundancy and permits neofunctionalization of the duplicated domains. Consistent
382 with this, we show that the outer LBD of Tgfbr2a attenuates signaling, acting as an inhibitory
383 module and illustrating domain-level neofunctionalization.

384 Together, these findings reveal that LBD duplication acts as a versatile mechanism for
385 modulating TGF β -receptor function, enabling the evolution of context-sensitive signaling
386 outputs. Given the pivotal role of TGF β -signaling in regulating cell fate, plasticity, and
387 migration, such domain-level adaptations likely contributed to the evolutionary diversification
388 of vertebrate body plans. Importantly, these natural strategies may inform the rational design
389 of synthetic TGF β modulators, such as multivalent ligand traps, with potential applications in
390 regenerative medicine and cancer therapy.

391

392 Material and Methods

393 Ethics and Animal Welfare Statement

394 Our research complies with all relevant ethical regulations; the relevant animal protection
395 committee of the Leibniz-IGB and the city of Berlin (LaGeSo) approved the animal use protocol
396 where relevant. *Anguilla anguilla* and *Cyprinus carpio* were kept under animal husbandry
397 permit ZH114 (LaGeSo, Berlin) at IGB; three other fish species (*Gnathonemus petersii*,
398 *Pantodon buchholzi*, *Erpetoichthys calabaricus*) were obtained from commercial dealers and
399 humanely euthanized using an overdose of buffered Tricaine PHARMAQ 1000 MG/G (MS222;
400 concentration: 500 mg/L), for commercial fish at the day of arrival at IGB. This ensured that no
401 pain, suffering, distress or lasting harm was inflicted on the animals. RNA samples of *Xenopus*
402 *laevis* were obtained from control groups of an animal experiment approved by the German
403 State of Health and Social Affairs (LaGeSo, Berlin, Germany; G0359/12).

404 Zebrafish experiments were performed in accordance with protocol BR22-1497 approved by
405 the Institutional Animal Care and Use Committee (IACUC) of the National University of
406 Singapore. Adult zebrafish were housed in recirculating aquaria systems at 28°C under a 14
407 hour/10 hour light/dark cycle in the fish facility of the Department of Biological Sciences (DBS)
408 at the National University of Singapore.

409 RNA isolation and cDNA synthesis

410 Taxon sampling includes selection from *Danio rerio* (fin – adult, whole larvae), *Xenopus laevis*
411 (brain, testis, liver and gonad mixture (adult), larvae), *Cyprinus carpio* (gonad, muscle, brain,
412 heart, fin – adult), *Gnathonemus petersii* (gonad, muscle, brain, heart, fin – adult), *Pantodon*
413 *buchholzi* (gonad, muscle, brain, heart, fin – adult), *Erpetoichthys calabaricus* (gonad, muscle,
414 brain, heart, fin – adult), *Anguilla anguilla* (gonad, muscle, brain, heart, fin – adult), and *Gallus*
415 *gallus* (DF1 cell line). Tissues of *Anguilla anguilla*, *Cyprinus carpio*, *Gnathonemus petersii*,
416 *Pantodon buchholzi*, *Erpetoichthys calabaricus* were stored in RNAlater (Thermo Fisher
417 Scientific) for 24 hours at 8°C, then drained and stored at -80°C until further processing. RNAs
418 were extracted using TRIzol Reagent (Thermo Fisher Scientific, Waltham, USA) according to
419 the supplier's recommendation and cleaned using the RNeasy Mini Kit (Qiagen). For synthesis
420 of *Danio rerio* and *Gallus gallus* cDNA, 1 µg of total RNA was reversely transcribed by
421 incubation with random primers (100 pmol µL⁻¹, Invitrogen) and M-MuLV reverse transcriptase
422 enzyme (New England Biolabs) following manufactures recommendations. Synthesis of cDNA
423 of *Xenopus laevis* and *Cyprinus carpio* was performed using iScript RT Supermix for RT-qPCR
424 kit (Biorad); 10 µL of RNA (concentration of 80 ng/µL) were randomly reverse-transcribed
425 following the manufactures recommendations.

426 RNA sequencing and *de novo* transcriptome assembly

427 For transcriptomics of *Anguilla anguilla*, *Gnathonemus petersii*, *Pantodon buchholzi* and
428 *Erpetoichthys calabaricus* muscle tissue, RNA and library processing and RNA-seq were
429 carried out by NOVOGENE (Cambridge, UK) on a NovaSeq 6000 PE 150, generating 9.3 –
430 10.0 Gb of raw data per sample. Raw data of each sample was processed using the fq2fa –
431 merge command from IDBA v1.1.1⁵² package to convert fastq to interleaved fasta format. The
432 corresponding files were assembled using idba_tran v 1.1.1 with default parameters. The
433 highest kmer transcript assemblies (kmer 60) were aligned to a custom protein database
434 (consisting of sequences for *ACVR1*, *ACVRL1*, *BMPR1A*, *BMPR1B*, *ACVR1B*, *ACVR1C*,
435 *TGFBR1*, *ACVR2A*, *ACVR2B*, *TGFBR2*, *BMPR2*, *AMHR2* and *INHBA* from *Siniperca chuatsi*
436 ⁵³ by blat⁵⁴ using parameters (-t=dnax -q=prot). Blat results were sorted by matching score and
437 the best hit transcripts were written to a bed6 formatted table and extracted from the
438 transcriptomes in 5' to 3' orientation using bedtools getfasta (-name -s)⁵⁵. The extracted
439 sequences were further processed as described below.

440 Phylogenetic analysis

441 Sequences of TGFβ receptor family orthologs were screened for LBD multimerization using
442 Ensembl gene tree function⁵⁶ and NCBI blast (<https://blast.ncbi.nlm.nih.gov/Blast.cgi>) against
443 available vertebrate transcriptomes and/or genomes. RNA-seq was performed for selected
444 species (*Gnathonemus petersii*, *Pantodon buchholzi*, *Erpetoichthys calabaricus*, *Anguilla*
445 *anguilla*) to complement missing information in respective taxa. In the absence of available
446 transcriptome data, ORFs were predicted in regions identified by nucleotide Blast of closely
447 related species using Augustus web interface (<https://bioinf.uni-greifswald.de/augustus/>)⁵⁷.

448 LBDs were predicted from amino acid sequences using NCBI Conserved Domain Search web
449 interface (<https://www.ncbi.nlm.nih.gov/Structure/cdd/wrpsb.cgi>)⁵⁸. Phylogenetic trees were
450 extracted from NCBI taxonomy CommonTree ([https://www.ncbi.nlm.nih.gov/Taxonomy/
451 CommonTree/wwwcmt.cgi](https://www.ncbi.nlm.nih.gov/Taxonomy/CommonTree/wwwcmt.cgi))⁵⁹ and represented using Interactive Tree of Life (iTOL) v6⁶⁰.
452 Species images were extracted from Adobe Stock (ID: #301044215, #327193716,
453 #370603116, #61858943, #115805136, #490808539, #125573996, #730691035,
454 #552043292, #227759813, #574310862, #35897212, #370612679) under the license of the
455 “Max Planck Institut für Molekulare Genetik, Berlin” and edited in Adobe Photoshop Version
456 26.8.0.

457 **RNA splicing analysis**

458 To analyse *TGFBR2* alternative splicing in horse and chicken, RNA-seq data from various
459 tissues (horse: PRJNA1017964; chicken: PRJEB26695) were aligned to the respective
460 reference genomes (chicken: GCA_016699485.1; horse: EquCab3.0) using STAR v2.7.9a.
461 Unique and multi-mapping reads for *TGFBR2* exons 1–5 were extracted from the SJ.out.tab
462 STAR output files using standard Python scripts. For sashimi plots, merged BAM files were
463 visualized in IGV, and coverage tracks were exported. Junction reads were manually corrected
464 by replacing them with unique and multi-mapping counts from the SJ.out.tab files. Reported
465 values correspond to the sum across all analysed replicates. In chicken samples, no reads
466 corresponding to the E1–E2' junction were detected. In horse, E2 inclusion relative to E2' was
467 calculated using uniquely mapping reads only. For the final table, only samples with at least
468 40 unique reads for the constitutive E4–E5 junction and tissues with at least two biological
469 replicates were included. For horse, selected tissues known to be regulated by TGFβ-signaling
470 are represented.

471 **RNA single cell analysis in zebrafish**

472 Single-cell RNA-seq data from the zebrahub atlas⁶¹ were downloaded and processed in R
473 using Seurat (v4)⁶². Cells with <500 detected features or genes expressed in <30 cells were
474 excluded. Data were normalized, variable features identified, and expression values scaled
475 prior to PCA (50 components) and UMAP embedding (first 30 PCs). Metadata annotations
476 from the zebrafish anatomy ontology available from the zebrahub atlas were used for cell-type
477 assignments. Gene expression was visualized on UMAPs and dot plots. For the intermediate
478 mesoderm and hematopoietic system, cells were stratified into four groups based on
479 *tgfbr2a*/*tgfbr2b* expression (double-positive, *tgfbr2a*⁺, *tgfbr2b*⁺, or double-negative).
480 Differential expression relative to double-negative cells was assessed using Seurat's
481 FindMarkers function, and pseudobulk-like expression profiles were generated by using
482 Seurat's AverageExpression function. Differentially expressed genes were filtered by a log2
483 FC ≥ 0.58 and an adjusted p-value ≤ 0.05. Significantly diff. exp. genes relative to double-
484 negative condition were compared using DeepVenn⁶³ (<https://www.deepvenn.com/>) and
485 visualized in Photoshop. gProfiler g:GOST⁶⁴ (<https://biit.cs.ut.ee/gprofiler/gost>) was used for
486 functional enrichment analysis of genes specifically enriched in d*Tgfbr2a*⁺ or d*Tgfbr2b*⁺ cells
487 compared to double-negative cells on indicated time points.

488 **Molecular cloning**

489 To functionally characterize TGFBR2 or BMPR2 receptors of *Danio rerio*, *Cyprinus carpio*,
490 *Xenopus laevis*, *Gnathonemus petersii*, *Gallus gallus* and *Equus caballus*, we generated an
491 N-terminally Halo-tagged receptor expression plasmid library (**Tab. 1**). For this, we used

492 various cloning methods including restriction-, Gibson-, blunt end- and deletion mutagenesis
493 cloning, specified for each animal below. All primers used for PCR are listed in (Tab. 2).
494 Cloning PCRs were carried out on a Peltier Thermal Cycler PTC-200. The elongation time was
495 adapted according to the product size (Phusion Pol. = 1kb/min). PCR products were resolved
496 by agarose gel electrophoresis and purified using NucleoSpin Gel and a PCR Clean-up kit
497 (Macherey-Nagel), according to the manufacturer's guidelines. Gibson cloning using
498 NEBuilder HiFi DNA Kit (New England BioLabs) was performed according to the
499 manufacturer's protocol. Final products were transformed in chemically competent DH5α *E.*
500 *coli* bacteria cells. All constructs were confirmed via Sanger sequencing followed by whole
501 plasmid sequencing. Expression is confirmed via Western blot (Sup. Fig. 20).

502

503 ***Danio rerio* and *Cyprinus carpio***

504 drTgfr2a, drTgfr2b and cTgfr2a were amplified from respective cDNA and subcloned into
505 a previously generated pcDNA3.1. hTGFR2-halo plasmid²¹ in between *EcoRI* and *NotI* sites,
506 replacing the original receptor ORF resulting in drTgfr2a-Halo, drTgfr2b-Halo and cTgfr2a-
507 Halo expression plasmids. Further, to generate drTgfr2a-LBDⁱⁿ-Halo, drTgfr2a-LBD^{out}-Halo,
508 cTgfr2a-LBDⁱⁿ-Halo and cTgfr2a-LBD^{out}-Halo constructs, deletion mutagenesis was
509 performed on drTgfr2a-Halo and cTgfr2a-Halo templates. Deletion primers were used to
510 flank either the inner or outer ligand binding domain sequences. Subsequently, PCR constructs
511 were ligated via blunt end ligation.

512

513 ***Gnathonemus petersii***

514 Following the RNA-seq analysis of *Gnathonemus petersii* heart tissue, we ordered the
515 synthesis of gnBmpr2a-pTwist-CMV plasmid at "Twist Bioscience" and amplified gnBmpr2a,
516 gnBmpr2a-LBD^{mid-in} and gnBmpr2a-LBDⁱⁿ. We then subcloned these constructs into
517 hTGFR2-Halo plasmid in between *EcoRI* and *NotI* sites, replacing the original receptor ORF
518 resulting in gnBmpr2a-Halo, gnBmpr2a-LBD^{mid-in}-Halo and gnBmpr2a-LBDⁱⁿ-Halo expression
519 plasmids. Further, to generate gnBmpr2a-LBD^{out}-Halo and gnBmpr2a-LBD^{mid}-Halo constructs,
520 Gibson cloning was performed on gnBmpr2a-Halo template.

521

522 ***Xenopus laevis***

523 xITgfr2L was amplified from respective cDNA and subcloned using Zero Blunt™ PCR
524 Cloning Kit (Thermo Fisher Scientific) according to the manufacturer's protocol into a pCR™-
525 Blunt-vector. The full length xITgfr2.L-Halo construct was synthesized by "Genewiz".
526 Consecutively, Gibson-cloning was performed on this vector. By this, we obtained xITgfr2.L-
527 LBDⁱⁿ-Halo, xITgfr2.L-LBD^{out}-Halo, xITgfr2.L-LBD^{mid-in}-Halo.

528

529 ***Equus caballus***

530 Due to high sequence identity between the inner and outer ligand binding domains, we
531 obtained a codon optimized eTGFR2-pTwist-CMV plasmid from "Twist Bioscience" and
532 amplified eTGFR2. We then subcloned this construct into hTGFR2-Halo plasmid in between
533 *EcoRI* and *NotI* sites, replacing the original receptor ORF resulting in eTGFR2-Halo. Further,
534 to generate eTGFR2-LBDⁱⁿ-Halo and eTGFR2-LBD^{out}-Halo constructs, Gibson cloning was
535 performed on eTGFR2-Halo template.

536

537 ***Gallus gallus***

538 gTGFR2 (ENSGALT00000018657.6) and gTGFR2-LBD^{out} (ENSGALT00000037691.5)
539 were amplified from respective cDNA and subcloned into hTGFR2-halo plasmid in between
540 *EcoRI* and *NotI* sites, replacing the original receptor ORF resulting in gTGFR2-Halo and
541 gTGFR2-LBD^{out}-Halo. The subcloned gTGFR2 ORF contained an additional exon in
542 between the kinase coding exon 6 and exon 7, which was removed by Gibson cloning.
543 Thereby, both gTGFR2 and gTGFR2-LBD^{out} variants encoded for the same kinase, making
544 a direct comparison of the duplicated LBD signaling competence possible. Further, to generate
545 gTGFR2-LBDⁱⁿ-Halo, deletion mutagenesis was performed on gTGFR2-Halo template.
546 Deletion primers were used to flank the outer ligand binding domain. Subsequently, PCR
547 constructs were ligated via blunt end ligation.

548 **Capped mRNA synthesis and microinjection in zebrafish**

549 To synthesize capped mRNA, the mMMESSAGE mMACHINE T7 Transcription Kit
550 (ThermoFisher) was used with *Dralll*-linearized dTgfr2a-Halo, dTgfr2a LBDⁱⁿ-Halo, dTgfr2a
551 LBD^{out}-Halo, and *Bful*-linearized dTgfr2b-Halo plasmids as templates, respectively. To
552 synthesize capped *PMT-mEGFP* (membrane bound EGFP) mRNA, the mMMESSAGE
553 mMACHINE SP6 Transcription Kit (ThermoFisher) was used with *NotI*-linearized *pcs2+-PMT-*
554 *mEGFP*^{65,66} plasmids as templates. The final concentrations of synthesized mRNAs were
555 measured by Qubit 4 Fluorometer (ThermoFisher) using Qubit™ RNA HS Assay Kit
556 (ThermoFisher). For microinjection, wild type (WT) embryos were collected immediately after
557 spawning and transferred to 0.3X Danieau's solution (17.4 mM NaCl, 0.21 mM KCl, 0.12 mM
558 MgSO₄, 0.18 mM Ca(NO₃)₂, 1.5 mM HEPES, pH = 7.2). Injected embryos were raised in a
559 28°C incubator until 22 hpf for screening and imaging. Embryonic stages were defined by hours
560 post fertilization (hpf) at 28°C and morphological features⁶⁷. To compare the respective effects
561 of dTgfr2a-Halo, dTgfr2a LBDⁱⁿ-Halo, dTgfr2a LBD^{out}-Halo and Tgfr2b-Halo in WT
562 embryos, 170 pg *dTgfr2a-Halo*, 148 pg *dTgfr2a LBDⁱⁿ-Halo*, 148 pg *dTgfr2a LBD^{out}-Halo*,
563 or 148 pg of *dTgfr2b-Halo* capped mRNAs were co-injected with 10 pg *PMT-mEGFP* at the
564 border between cytoplasm and yolk of 1-cell stage WT embryos, respectively.

565 **Fluorescence screening and brightfield imaging of dTgfr2-Halo** 566 **injected zebrafish embryos**

567 Injected embryos were incubated in a 28°C incubator and screened for mEGFP fluorescence
568 at 22 hpf. mEGFP-positive embryos were characterized into three categories (normal, cyclopia
569 and ventralized) based on eye, head and trunk morphologies for quantification. Representative
570 embryos were imaged under a stereomicroscope (Nikon, SMZ18).

571 **Cell culture**

572 COS-7 and HEK293T cells were obtained from the German Collection of Microorganisms and
573 Cell Cultures (DSMZ) and cultured in Dulbecco's Modified Eagle's Medium (DMEM)
574 supplemented with 10% FCS, 2 mM L-glutamine and penicillin (100 units/mL) / streptomycin
575 (100 µg/mL) (DMEM full medium) in a humidified atmosphere at 37 °C and 5% CO₂ (v/v). COS-
576 7 and HEK293T cells were maintained in T175 flasks and split 1:5 or 1:10, depending on need
577 and were kept sub-confluent. For passaging, cells were washed once with PBS before being
578 removed from the flasks surface with trypsin/EDTA (0.05/0.02% in PBS).

579 **SDS-PAGE & Western-blotting**

580 For sodium dodecyl sulphate polyacrylamide gel-electrophoresis (SDS-PAGE), cells
581 transiently expressing Halo-receptors were lysed in 150 μ L Laemmli buffer and frozen at -20
582 $^{\circ}$ C. To ensure a homogeneous loading, cell lysate was pulled through a 1 ml syringe and boiled
583 for 10 min at 95 $^{\circ}$ C before loading onto 10% polyacrylamide gels. After performed gel-
584 electrophoresis, proteins were transferred onto Methanol-activated PVDF membranes by
585 Western-blotting. Next, membranes were blocked for 1 hour in a solution containing 0.1% TBS-
586 T and 3% w/v bovine serum albumin (BSA), then washed three times in 0.1% TBS-T and
587 incubated with indicated primary antibodies overnight at 4 $^{\circ}$ C. Primary antibodies: anti-Halo
588 (ProMega; #G9211; monoclonal mouse antibody), anti-pSMAD2 Ser465/467 (Cell Signaling;
589 #3108; monoclonal rabbit antibody), and anti-GAPDH (Cell Signaling; #2118; monoclonal
590 rabbit antibody) were used at a 1:1000 dilution in 3% w/v BSA/ TBS-T solution. For HRP-based
591 detection, membranes were incubated with secondary goat- α -mouse or goat- α -rabbit IgG HRP
592 conjugates (\pm 0.8 mg/ml, Dianova; #111-035-144, #115-035-068) for 1 hour at a dilution of
593 1:10000. Chemiluminescent reactions were processed using WesternBright Quantum HRP
594 substrate (Advansta Inc.) and documented on a FUSION FX7 digital imaging system.

595 **Confocal microscopy & Ligand Surface Binding Assay (LSBA)**

596 LSBA assay and consecutive image analysis and quantification was previously described in
597 detail for SiR-d12-hTGF β 1 and Cy5-hActivin A²¹. In brief, for visualization of SiR-d12-hTGF β 1
598 and Cy5-hActivin A ligand binding, 200.000 COS-7 cells / well were seeded in 1 mL DMEM full
599 medium on glass cover slips in a 12 well plate. On the following day, cells were transfected
600 with desired constructs (500 ng DNA per well) using Lipofectamine2000 according to the
601 manufacturer's instructions. The day after, cells were washed with PBS and, additionally to 0.5
602 mM fluorescent HaloTag-ligand CA-Alexa488 (Alexa Fluor 488, Promega, #G1002),
603 simultaneously incubated with saturating conc. of SiR-d12-hTGF β 1 or Cy5-hActivin A for
604 30 minutes at 4 $^{\circ}$ C. Subsequently, cells were washed once with ice-cold PBS before fixation
605 with 100% methanol for 5 minutes. Cells were washed again with PBS and mounted with
606 Fluoromount G (Invitrogen, 00-4958-02). Confocal images were acquired on a commercial
607 expert line Abberior STED microscope, using the Inspector software from Abberior
608 Instruments (Version 16.3) in line-scanning confocal mode; objective lens: 100X NA1.4 (oil
609 [UPLS], pinhole: 1.0 AU, range: 75 μ m x 75 μ m, confocal pixel size: 60 nm, pixel dwell time:
610 5/10 μ s. Images were acquired using 485 nm (20% laser power) and 640 nm excitation (20%
611 laser power). The detection windows were set to 500 – 540 nm and 650 – 750 nm. Confocal
612 raw data were post-processed and adjusted for color and contrast (linear adjustments
613 maintained for confocal datasets represented within one figure) using Fiji (ImageJ) software
614 and Adobe Photoshop (Adobe Systems). Surface binding quantification of SiR-d12-hTGF β 1
615 and Cy5-hActivin A on COS-7 cells transiently expressing Halo-Receptor constructs was
616 performed with Fiji. Per cell, four regions of interest (ROI) (100 μ m²) were chosen, and the raw
617 integrated intensity (RawIntDen) of each ROI was measured both in receptor and ligand
618 channels. Per condition, 30 cells were quantified in total in 3 independent experiments.
619 Receptor-ligand binding was calculated relative to intensity values of untransfected COS-7
620 cells, representing endogenous ligand-receptor binding. Normalized RawIntDen values of
621 receptors and ligands were plotted in GraphPad Prism 10.5 (GraphPad Software Inc.).

622 **Dual Luciferase Reporter Gene Assay**

623 For dual luciferase reporter gene assay, 50.000 HEK293T cells / well were seeded in 200 μ L
624 DMEM full medium in a 96 well plate. On the following day, cells were transfected with 50 ng

625 of corresponding Halo-tagged receptors constructs together with 50 ng of SMAD2/3 sensitive
626 (CAGA)₁₂ luciferase reporter. A constitutively expressing construct encoding renilla luciferase
627 (RL-TK; Promega) was co-transfected (30 ng) as internal control. The next day, cells were
628 starved in serum-free medium for 3 h before stimulation with 0.2 nM rhTGFβ1 (PeproTech,
629 Hamburg, Germany) or 0.02 nM rhActivin A (Gift from Marko Hyvönen) for 24 h. Cell lysis was
630 performed using passive lysis buffer (Promega, # E1910) and measurement of luciferase
631 activity was carried out according to manufacturer's instructions using a TECAN Spark plate
632 reader. Experiments testing the TGFBR2 ortholog signaling competence were normalized
633 against the rhTGFβ1 response of hTGFBR2-Halo.

634 **Structure prediction and interface energy calculations**

635 The structure of the receptor and ligand complexes were first predicted using AlphaFold2
636 multimer^{68,69} using the single receptor ECDs and two ligand chains (either hActivin A, hTGFβ1
637 or the respective animal variants) for the ligand homodimers. In order to obtain a physically
638 more validated structure while simultaneously scoring the interface, first coordinate
639 constrained relaxation protocol was performed to optimize H-bonds based on the Rosetta
640 Energy Function 2015 (ref2015_cst) within RosettaScripts. Local Monte-Carlo-based protein-
641 protein docking using RosettaScripts²⁰ was performed in 2500 replicas. Here, first, the
642 "Docking" mover was used with low resolution (backbone plus centroid) flags before a high
643 resolution (full atom) docking (using ref2015 scoring function). Other parameters as distance
644 perturbation and angle perturbation were left on default. The Interface RMSD (iRMSD) was
645 plotted against the score of the interface residues (i_SC) of the top 500 structures (determined
646 by i_SC) and mean binding energies were calculated. Lower interface score correlates with
647 favourable interface energies. Lower iRMSD correlates to docking structures closer to the
648 starting AlphaFold2-multimer conformation. For structural representation, the top 10 hits
649 showing the lowest i_SC were structurally investigated for the final homology model. All used
650 scripts for structure prediction and interface energy calculations are available under
651 <https://github.com/agknaus/Jatzlau-Trumpp-et-al.-structural-computational-analysis/>.

652 **Molecular Clock and Evolutionary Rate Analysis of LBDs**

653 Amino-acid sequences of LBD regions were aligned in MEGA X⁷⁰. Alignments were generated
654 using the MUSCLE algorithm with default parameters. Pairwise evolutionary distances
655 between LBD sequences were calculated in MEGA X using the Analyze → Compute Pairwise
656 Distances function. Distances were estimated under the Jones–Taylor–Thornton (JTT)
657 substitution model with gamma-distributed rate heterogeneity ($\Gamma = 1.0$) and a homogeneous
658 substitution pattern among lineages. The substitution type was set to Amino acid, and gaps or
659 missing data were handled using pairwise deletion. Variance estimation was performed using
660 the bootstrap method with 1000 replicates. For each focal species (chicken, horse, salmon,
661 zebrafish), distances were calculated between its inner LBD and the orthologous inner LBDs
662 of other species within the same clade. Distances between the two LBD copies within the focal
663 species were computed separately to quantify intra-species divergence associated with the
664 domain duplication event.

665 Species divergence times for all pairwise comparisons were obtained directly from
666 TimeTree.org⁷¹. These values were used as the independent variable in all molecular-clock
667 analyses. For each clade, the amino-acid substitution rate (r, substitutions per site per million
668 years) was estimated by performing a weighted linear regression of pairwise amino-acid

669 distances against their corresponding TimeTree-derived species divergence times. The slope
670 of the regression provided the clade-specific molecular-clock rate for the inner LBD domain.
671 The observed amino-acid distance between the two LBD copies within each focal species was
672 divided by the clade-specific molecular-clock rate to obtain the duplication-specific evolutionary
673 rate (r_{dup}). This value reflects the effective rate of amino-acid substitution between the two
674 paralogous domains since their duplication.

675 **Statistical analysis**

676 All statistical tests were performed using GraphPad Prism version 10.5.0 software and are
677 listed in the figure legends. Normal distribution of data sets was tested with the Shapiro-Wilk
678 normality test. In cases of failure to reject the null hypothesis, the ANOVA and Tukey's or
679 Dunnett post hoc test were used to check for statistical significance under the normality
680 assumption. For all experiments statistical significance was assigned, with an alpha-level of
681 $p < 0.05$.

682 **Graphical schemes and figures**

683 Figures were generated and assembled using PyMOL, GraphPad Prism, Biorender.com and
684 Adobe® Photoshop (Adobe Systems, San José, USA).

685 **Acknowledgments**

686 J.J. and P.K. acknowledge the support from Deutsche Forschungsgemeinschaft DFG
687 (SFB1444) and the Einstein Center ECRT). M.T. and L.O. was supported by the Max Planck
688 Research School IMPRS-BAC. Funding has been in part provided by the German Research
689 Foundation (DFG) STO493/8-1 to MS. CW was funded by grants from the Singapore Ministry
690 of Education (grant numbers MOE-2016-T3-1-005 and MOE-T2EP30221-0008). Further, the
691 authors would like to thank Francesca Bottanelli (Freie Universität Berlin) for providing access
692 to her commercial expert line Abberior STED microscope. W.B. was supported by Berlin–
693 Brandenburg School for Regenerative Therapies. The authors would like to thank BioRender
694 for providing a platform to generate elements of Figure 1 – 7, Supplemental Figure 3 – 5,
695 Supplemental Figure 8 – 10, Supplemental Figure 17 (Created in BioRender. Trumpp, M.
696 (2025) <https://BioRender.com/8p64dhh>).

697 **Author Contributions**

698 J.J., M.T. designed the study, evaluated the data and generated all figures; M.T., J.J., J.K.,
699 Y.L., H.B. and performed the experiments; J.J. and M.T. performed the phylogenetic analysis;
700 L.O., J.K. performed receptor homology modeling & docking calculations; M.T. produced
701 hTGF β 1-SiR-d12; Y.L. performed zebrafish experiments; M.S. collected the tissue samples of
702 *G. petersii*, *P. buchholzi*, *E. calabaricus*, *A. anguilla* and *X. laevis*, and prepared RNA and
703 cDNA and discussed ancient/recent genome duplications; C.W. provided *D. rerio* cDNA
704 samples. M.T., J.J., J.K, and H.B. cloned all Halo-receptor constructs. H.K. processed the
705 transcriptome data and analyzed the results. M.P. performed RNA splicing analysis, P.M.
706 analyzed scRNA-seq data, W.B. analyzed LSBA data; P.K., M.S., C.W., and S.M. discussed
707 the project and gave critical input. J.J., M.T. and P.K. wrote the manuscript; all authors
708 commented on the manuscript.

709 **Conflict of Interest**

710 The authors declare no competing interest.

711 **Data availability**

712 The data supporting the findings of this study are available from the corresponding authors
713 upon request. RNA raw sequence datasets for *Gnathonemus petersii*, *Pantodon buchholzi*,
714 *Erpetoichthys calabaricus* and *Anguilla anguilla* have been submitted to NCBI/SRA under the
715 BioProject accession: PRJNA1314022.

716

717 References

718

- 719 1 Pires-daSilva, A. & Sommer, R. J. The evolution of signalling pathways in animal development.
720 *Nat Rev Genet* **4**, 39-49 (2003). <https://doi.org/10.1038/nrg977>
- 721 2 Barberan, S., Martin-Duran, J. M. & Cebria, F. Evolution of the EGFR pathway in Metazoa and
722 its diversification in the planarian *Schmidtea mediterranea*. *Sci Rep* **6**, 28071 (2016).
723 <https://doi.org/10.1038/srep28071>
- 724 3 Bogdan, S. & Klambt, C. Epidermal growth factor receptor signaling. *Curr Biol* **11**, R292-295
725 (2001). [https://doi.org/10.1016/s0960-9822\(01\)00167-1](https://doi.org/10.1016/s0960-9822(01)00167-1)
- 726 4 Itoh, N. & Ornitz, D. M. Evolution of the Fgf and Fgfr gene families. *Trends Genet* **20**, 563-569
727 (2004). <https://doi.org/10.1016/j.tig.2004.08.007>
- 728 5 Kipyushina, Y. O., Yakovlev, K. V. & Odintsova, N. A. Vascular endothelial growth factors: A
729 comparison between invertebrates and vertebrates. *Cytokine Growth Factor Rev* **26**, 687-695
730 (2015). <https://doi.org/10.1016/j.cytogfr.2015.04.001>
- 731 6 Trumpp, M. *et al.* Characterization of Fibrodysplasia Ossificans Progressiva relevant
732 *Acvr1/Acvr2* Activin receptors in medaka (*Oryzias latipes*). *Plos One* **18** (2023).
733 <https://doi.org/10.1371/journal.pone.0291379>
- 734 7 Zinski, J., Tajer, B. & Mullins, M. C. TGF- β Family Signaling in Early Vertebrate Development.
735 *Cold Spring Harb Perspect Biol* **10** (2018). <https://doi.org/10.1101/cshperspect.a033274>
- 736 8 Hiepen, C., Yadin, D., Rikeit, P., Dorpholz, G. & Knaus, P. Actions from head to toe: An update
737 on Bone/Body Morphogenetic Proteins in health and disease. *Cytokine Growth Factor Rev* **27**,
738 1-11 (2016). <https://doi.org/10.1016/j.cytogfr.2015.12.006>
- 739 9 Nickel, J. & Mueller, T. D. Specification of BMP Signaling. *Cells* **8** (2019).
740 <https://doi.org/10.3390/cells8121579>
- 741 10 Yadin, D., Knaus, P. & Mueller, T. D. Structural insights into BMP receptors: Specificity,
742 activation and inhibition. *Cytokine Growth Factor Rev* **27**, 13-34 (2016).
743 <https://doi.org/10.1016/j.cytogfr.2015.11.005>
- 744 11 Bragdon, B. *et al.* Bone morphogenetic proteins: a critical review. *Cell Signal* **23**, 609-620
745 (2011). <https://doi.org/10.1016/j.cellsig.2010.10.003>
- 746 12 Upadhyay, A., Moss-Taylor, L., Kim, M. J., Ghosh, A. C. & O'Connor, M. B. TGF- β Family
747 Signaling in *Drosophila*. *Cold Spring Harb Perspect Biol* **9** (2017).
748 <https://doi.org/10.1101/cshperspect.a022152>
- 749 13 Huminiacki, L. *et al.* Emergence, development and diversification of the TGF-beta signalling
750 pathway within the animal kingdom. *BMC Evol Biol* **9**, 28 (2009).
751 <https://doi.org/10.1186/1471-2148-9-28>
- 752 14 Zheng, S., Long, J., Liu, Z., Tao, W. & Wang, D. Identification and Evolution of TGF- β Signaling
753 Pathway Members in Twenty-Four Animal Species and Expression in *Tilapia*. *Int J Mol Sci* **19**
754 (2018). <https://doi.org/10.3390/ijms19041154>
- 755 15 Hoegg, S., Brinkmann, H., Taylor, J. S. & Meyer, A. Phylogenetic timing of the fish-specific
756 genome duplication correlates with the diversification of teleost fish. *J Mol Evol* **59**, 190-203
757 (2004). <https://doi.org/10.1007/s00239-004-2613-z>
- 758 16 Ning, B. *et al.* Genomic organization, intragenic tandem duplication, and expression analysis
759 of chicken TGFBR2 gene. *Poultry Science* **101**, 102169 (2022).
760 <https://doi.org/https://doi.org/10.1016/j.psj.2022.102169>
- 761 17 Heinecke, K. *et al.* Receptor oligomerization and beyond: a case study in bone
762 morphogenetic proteins. *Bmc Biol* **7**, 59 (2009). <https://doi.org/10.1186/1741-7007-7-59>
- 763 18 Sebald, W., Nickel, J., Zhang, J.-L. & Mueller, T. D. Molecular recognition in bone
764 morphogenetic protein (BMP)/receptor interaction. *Biological Chemistry* **385**, 697-710
765 (2004). <https://doi.org/doi:10.1515/BC.2004.086>

766 19 Chu, K. Y., Malik, A., Thamilselvan, V. & Martinez-Hackert, E. Type II BMP and activin
767 receptors BMPR2 and ACVR2A share a conserved mode of growth factor recognition. *J Biol*
768 *Chem* **298**, 102076 (2022). <https://doi.org/10.1016/j.jbc.2022.102076>

769 20 Fleishman, S. J. *et al.* RosettaScripts: a scripting language interface to the Rosetta
770 macromolecular modeling suite. *Plos One* **6**, e20161 (2011).
771 <https://doi.org/10.1371/journal.pone.0020161>

772 21 Jatzlau, J. *et al.* A versatile Halo- and SNAP-tagged BMP/TGF β receptor library for
773 quantification of cell surface ligand binding. *Commun Biol* **6** (2023).
774 <https://doi.org/10.1038/s42003-022-04388-4>

775 22 Radaev, S. *et al.* Ternary Complex of Transforming Growth Factor- β 1 Reveals Isoform-specific
776 Ligand Recognition and Receptor Recruitment in the Superfamily*. *Journal of Biological*
777 *Chemistry* **285**, 14806-14814 (2010).
778 <https://doi.org/https://doi.org/10.1074/jbc.M109.079921>

779 23 Sun, J. *et al.* Origination of New Immunological Functions in the Costimulatory Molecule B7-
780 H3: The Role of Exon Duplication in Evolution of the Immune System. *Plos One* **6**, e24751
781 (2011). <https://doi.org/10.1371/journal.pone.0024751>

782 24 Gunning, P. W., Schevzov, G., Kee, A. J. & Hardeman, E. C. Tropomyosin isoforms: diving
783 rods for actin cytoskeleton function. *Trends Cell Biol* **15**, 333-341 (2005).
784 <https://doi.org/10.1016/j.tcb.2005.04.007>

785 25 Piera-Velazquez, S. & Jimenez, S. A. Endothelial to Mesenchymal Transition: Role in
786 Physiology and in the Pathogenesis of Human Diseases. *Physiol Rev* **99**, 1281-1324 (2019).
787 <https://doi.org/10.1152/physrev.00021.2018>

788 26 Goumans, M.-J., van Zonneveld, A. J. & ten Dijke, P. Transforming Growth Factor β -Induced
789 Endothelial-to-Mesenchymal Transition: A Switch to Cardiac Fibrosis? *Trends in*
790 *Cardiovascular Medicine* **18**, 293-298 (2008).
791 <https://doi.org/https://doi.org/10.1016/j.tcm.2009.01.001>

792 27 Lamouille, S., Xu, J. & Derynck, R. Molecular mechanisms of epithelial-mesenchymal
793 transition. *Nature Reviews Molecular Cell Biology* **15**, 178-196 (2014).
794 <https://doi.org/10.1038/nrm3758>

795 28 Dooley, S. & ten Dijke, P. TGF- β in progression of liver disease. *Cell Tissue Res* **347**, 245-256
796 (2012). <https://doi.org/10.1007/s00441-011-1246-y>

797 29 Preiß, H. *et al.* Regulation of Nodal signaling propagation by receptor interactions and
798 positive feedback. *Elife* **11** (2022). <https://doi.org/10.7554/eLife.66397>

799 30 Pomreinke, A. P. *et al.* Dynamics of BMP signaling and distribution during zebrafish dorsal-
800 ventral patterning. *eLife* **6**, e25861 (2017). <https://doi.org/10.7554/eLife.25861>

801 31 Verstraeten, A., Alaerts, M., Van Laer, L. & Loeys, B. Marfan Syndrome and Related Disorders:
802 25 Years of Gene Discovery. *Hum Mutat* **37**, 524-531 (2016).
803 <https://doi.org/10.1002/humu.22977>

804 32 Ye, D. *et al.* Insights into bone morphogenetic proteins in cardiovascular diseases. *Front*
805 *Pharmacol* **14**, 1125642 (2023). <https://doi.org/10.3389/fphar.2023.1125642>

806 33 Kaplan, F. S., Al Mukaddam, M., Stanley, A., Towler, O. W. & Shore, E. M. Fibrodysplasia
807 ossificans progressiva (FOP): A disorder of osteochondrogenesis. *Bone* **140**, 115539 (2020).
808 <https://doi.org/10.1016/j.bone.2020.115539>

809 34 Hinck, A. P., Mueller, T. D. & Springer, T. A. Structural Biology and Evolution of the TGF- β
810 Family. *Cold Spring Harb Perspect Biol* **8** (2016).
811 <https://doi.org/10.1101/cshperspect.a022103>

812 35 Jaillon, O. *et al.* Genome duplication in the teleost fish Tetraodon nigroviridis reveals the
813 early vertebrate proto-karyotype. *Nature* **431**, 946-957 (2004).
814 <https://doi.org/10.1038/nature03025>

815 36 Nakatani, Y., Takeda, H., Kohara, Y. & Morishita, S. Reconstruction of the vertebrate ancestral
816 genome reveals dynamic genome reorganization in early vertebrates. *Genome Res* **17**, 1254-
817 1265 (2007). <https://doi.org/10.1101/gr.6316407>

818 37 Session, A. M. *et al.* Genome evolution in the allotetraploid frog *Xenopus laevis*. *Nature* **538**,
819 336-343 (2016). <https://doi.org/10.1038/nature19840>

820 38 Wang, J.-T., Li, J.-T., Zhang, X.-F. & Sun, X.-W. Transcriptome analysis reveals the time of the
821 fourth round of genome duplication in common carp (*Cyprinus carpio*). *BMC Genomics* **13**, 96
822 (2012). <https://doi.org/10.1186/1471-2164-13-96>

823 39 Gundappa, M. K. *et al.* Genome-Wide Reconstruction of Rediploidization Following
824 Autopolyploidization across One Hundred Million Years of Salmonid Evolution. *Molecular*
825 *Biology and Evolution* **39** (2021). <https://doi.org/10.1093/molbev/msab310>

826 40 Deng, Z. *et al.* TGF- β signaling in health, disease and therapeutics. *Signal Transduction and*
827 *Targeted Therapy* **9**, 61 (2024). <https://doi.org/10.1038/s41392-024-01764-w>

828 41 Herpin, A., Lelong, C. & Favrel, P. Transforming growth factor- β -related proteins: an ancestral
829 and widespread superfamily of cytokines in metazoans. *Developmental & Comparative*
830 *Immunology* **28**, 461-485 (2004). <https://doi.org/https://doi.org/10.1016/j.dci.2003.09.007>

831 42 Rivera, A. M. & Swanson, W. J. The Importance of Gene Duplication and Domain Repeat
832 Expansion for the Function and Evolution of Fertilization Proteins. *Front Cell Dev Biol* **10**,
833 827454 (2022). <https://doi.org/10.3389/fcell.2022.827454>

834 43 Kuhl, H. *et al.* Multi-genome comparisons reveal gain-and-loss evolution of anti-Mullerian
835 hormone receptor type 2 as a candidate master sex-determining gene in Percidae. *Bmc Biol*
836 **22**, 141 (2024). <https://doi.org/10.1186/s12915-024-01935-9>

837 44 Wen, M. *et al.* An ancient truncated duplication of the anti-Müllerian hormone receptor type
838 2 gene is a potential conserved master sex determinant in the Pangasiidae catfish family.
839 *Molecular Ecology Resources* **22**, 2411-2428 (2022).
840 <https://doi.org/https://doi.org/10.1111/1755-0998.13620>

841 45 Qu, M. *et al.* Seadragon genome analysis provides insights into its phenotype and sex
842 determination locus. *Sci Adv* **7** (2021). <https://doi.org/10.1126/sciadv.abg5196>

843 46 Feron, R. *et al.* Characterization of a Y-specific duplication/insertion of the anti-Mullerian
844 hormone type II receptor gene based on a chromosome-scale genome assembly of yellow
845 perch, *Perca flavescens*. *Mol Ecol Resour* **20**, 531-543 (2020). <https://doi.org/10.1111/1755-0998.13133>

846

847 47 Suga, H., Ono, K. & Miyata, T. Multiple TGF- β receptor related genes in sponge and ancient
848 gene duplications before the parazoan–eumetazoan split 1. *FEBS Letters* **453**, 346-350
849 (1999). [https://doi.org/https://doi.org/10.1016/S0014-5793\(99\)00749-8](https://doi.org/https://doi.org/10.1016/S0014-5793(99)00749-8)

850 48 Herpin, A. *et al.* Structural and functional evidence for a singular repertoire of BMP receptor
851 signal transducing proteins in the lophotrochozoan *Crassostrea gigas* suggests a shared
852 ancestral BMP/activin pathway. *Febs j* **272**, 3424-3440 (2005).
853 <https://doi.org/10.1111/j.1742-4658.2005.04761.x>

854 49 Goebel, E. J., Hart, K. N., McCoy, J. C. & Thompson, T. B. Structural biology of the TGF β family.
855 *Exp Biol Med (Maywood)* **244**, 1530-1546 (2019).
856 <https://doi.org/10.1177/1535370219880894>

857 50 Saito, T. *et al.* Structural Basis of the Human Endoglin-BMP9 Interaction: Insights into BMP
858 Signaling and HHT1. *Cell Reports* **19**, 1917-1928 (2017).
859 <https://doi.org/https://doi.org/10.1016/j.celrep.2017.05.011>

860 51 Kim, S. K., Henen, M. A. & Hinck, A. P. Structural biology of betaglycan and endoglin,
861 membrane-bound co-receptors of the TGF-beta family. *Exp Biol Med (Maywood)* **244**, 1547-
862 1558 (2019). <https://doi.org/10.1177/1535370219881160>

863 52 Peng, Y. *et al.* IDBA-tran: a more robust de novo de Bruijn graph assembler for
864 transcriptomes with uneven expression levels. *Bioinformatics* **29**, i326-i334 (2013).
865 <https://doi.org/10.1093/bioinformatics/btt219>


866 53 He, S. *et al.* Mandarin fish (Sinipercaidae) genomes provide insights into innate predatory
867 feeding. *Commun Biol* **3**, 361 (2020). <https://doi.org/10.1038/s42003-020-1094-y>

868 54 Kent, W. J. BLAT—The BLAST-Like Alignment Tool. *Genome Research* **12**, 656-664 (2002).
869 <https://doi.org/10.1101/gr.229202>

870 55 Quinlan, A. R. & Hall, I. M. BEDTools: a flexible suite of utilities for comparing genomic
871 features. *Bioinformatics* **26**, 841-842 (2010). <https://doi.org/10.1093/bioinformatics/btq033>
872 56 Dyer, S. C. *et al.* Ensembl 2025. *Nucleic Acids Research* **53**, D948-D957 (2024).
873 <https://doi.org/10.1093/nar/gkae1071>
874 57 Keller, O., Kollmar, M., Stanke, M. & Waack, S. A novel hybrid gene prediction method
875 employing protein multiple sequence alignments. *Bioinformatics* **27**, 757-763 (2011).
876 <https://doi.org/10.1093/bioinformatics/btr010>
877 58 Wang, J. *et al.* The conserved domain database in 2023. *Nucleic Acids Res* **51**, D384-d388
878 (2023). <https://doi.org/10.1093/nar/gkac1096>
879 59 Schoch, C. L. *et al.* NCBI Taxonomy: a comprehensive update on curation, resources and
880 tools. *Database (Oxford)* **2020** (2020). <https://doi.org/10.1093/database/baaa062>
881 60 Letunic, I. & Bork, P. Interactive Tree of Life (iTOL) v6: recent updates to the phylogenetic
882 tree display and annotation tool. *Nucleic Acids Res* **52**, W78-w82 (2024).
883 <https://doi.org/10.1093/nar/gkae268>
884 61 Lange, M. *et al.* Zebrahub – Multimodal Zebrafish Developmental Atlas Reveals the State-
885 Transition Dynamics of Late-Vertebrate Pluripotent Axial Progenitors. *bioRxiv*,
886 2023.2003.2006.531398 (2023). <https://doi.org/10.1101/2023.03.06.531398>
887 62 Hao, Y. *et al.* Integrated analysis of multimodal single-cell data. *Cell* **184**, 3573-3587.e3529
888 (2021). <https://doi.org/https://doi.org/10.1016/j.cell.2021.04.048>
889 63 Hulsen, T. DeepVenn--a web application for the creation of area-proportional Venn diagrams
890 using the deep learning framework Tensorflow. js. *arXiv preprint arXiv:2210.04597* (2022).
891 64 Kolberg, L. *et al.* g:Profiler—interoperable web service for functional enrichment analysis and
892 gene identifier mapping (2023 update). *Nucleic Acids Research* **51**, W207-W212 (2023).
893 <https://doi.org/10.1093/nar/gkad347>
894 65 Balasubramanian, H., Sankaran, J., Pandey, S., Goh, C. J. H. & Wohland, T. The dependence of
895 EGFR oligomerization on environment and structure: A camera-based N&B study. *Biophys J*
896 **121**, 4452-4466 (2022). <https://doi.org/10.1016/j.bpj.2022.11.003>
897 66 Le, Y. *et al.* Midkine-a interacts with Ptptr1b to regulate neural plate convergence and
898 midline formation in the developing zebrafish hindbrain. *Dev Biol* **521**, 52-74 (2025).
899 <https://doi.org/10.1016/j.ydbio.2025.02.004>
900 67 Kimmel, C. B., Ballard, W. W., Kimmel, S. R., Ullmann, B. & Schilling, T. F. Stages of embryonic
901 development of the zebrafish. *Dev Dyn* **203**, 253-310 (1995).
902 <https://doi.org/10.1002/aja.1002030302>
903 68 Jumper, J. *et al.* Highly accurate protein structure prediction with AlphaFold. *Nature* **596**,
904 583-589 (2021). <https://doi.org/10.1038/s41586-021-03819-2>
905 69 Evans, R. *et al.* Protein complex prediction with AlphaFold-Multimer. *bioRxiv*,
906 2021.2010.2004.463034 (2021). <https://doi.org/10.1101/2021.10.04.463034>
907 70 Kumar, S., Stecher, G., Li, M., Knyaz, C. & Tamura, K. MEGA X: Molecular Evolutionary
908 Genetics Analysis across Computing Platforms. *Mol Biol Evol* **35**, 1547-1549 (2018).
909 <https://doi.org/10.1093/molbev/msy096>
910 71 Kumar, S. *et al.* TimeTree 5: An Expanded Resource for Species Divergence Times. *Mol Biol*
911 *Evol* **39** (2022). <https://doi.org/10.1093/molbev/msac174>

912

913 Main Figures




914
 915 **Figure 1: Convergent evolution of TGFβ & BMP-Receptor LBD multiplication in ray-**
 916 **finned fish.** Evolutionary tree displaying the relationship between different ray-finned fish
 917 clades. Ligand Binding Domain (LBD) duplication events (circles) occurred at least 5 times in
 918 four BMP and TGFβ-Receptor genes homologs (ACVR1, ACVR1L, BMPR2 and TGFB2).
 919 Additionally, LBD triplication events have occurred 4 times subsequently or in parallel (ACVR1,
 920 ACVR1L and BMPR2). Vertebrate-specific (2R), teleost-specific (3R) and carp-specific (4R)
 921 genome duplication events are indicated. Number of filled circles represent 1 to 3 LBDs.
 922 Transcripts are either validated by RNA-seq or predicted genes from available genomes
 923 assemblies (dashed-line).

924


925

TGFβ receptor 2 LBD multiplication in Jawed vertebrates (*Gnathostomata*)



926
 927
 928
 929
 930
 931
 932
 933
 934
 935
 936

Figure 2: Convergent LBD multiplication in TGFBR2 orthologs of jawed vertebrates. Evolutionary tree displaying the relationship of jawed vertebrates. Ligand Binding Domain (LBD) duplication events (circles) occurred at least 4 times in the TGFβ-Receptor type 2 genes paralogs *TGFBR2* and *TGFBR2L*. Additionally, *TGFBR2* LBD triplication events have occurred 2 times independently in different amphibian clades. Vertebrate-specific ancestral whole-genome duplication (2R) is indicated and gave rise to the paralogs *TGFBR2* and *TGFBR2L*. *TGFBR2L* has been lost in all mammals, some bird and amphibian species. Number of filled circles represent 1 to 3 LBDs. Transcripts are all validated by RNA-seq.



937

938 **Figure 3: Inner LBD conveys signaling competence of LBD multimerized BMPR2**
 939 **ortholog.** (A) Scheme of BMPR2 LBD sequence identity comparison relative to respective
 940 inner LBD within *G. petersii*, *G. niloticus* and *E. calabaricus*. (B) Structure of hActivin A with
 941 the LBD interface of hBMPR2 obtained via Rosetta docking starting from an AlphaFold2-
 942 multimer prediction. Interaction is facilitated by finger motif 3 (F3-loop) and A-loop of receptor
 943 LBD. (C) Molecular surface of hBMPR2 LBD showing the hActivin A interface, residues forming
 944 polar or hydrophobic contacts are colored in pink and gray, respectively (left). Sequence
 945 alignment of BMPR2 LBDs of *H. sapiens*, *G. petersii*, *G. niloticus* and *E. calabaricus* LBDs with
 946 hActivin A contact residues and critical backbone cysteins (teal) highlighted; interaction sites
 947 F3-loop and A-loop are indicated with colored lines (right). (D) Cartoon and stick
 948 representation of respective animal receptor LBD interaction with hActivin A (A-loop) based on


949 AlphaFold2-multimer models PyMOL was used for image representation. **(E, left)** Illustration
950 of *G. petersii* Bmpr2a 3 LBD receptor domain structure as reference, highlighting the inner
951 (pink), middle (green) and outer (blue) ligand binding domain. **(E, right)** *In silico* interface
952 analysis via Rosetta docking of hActivin A interactions with single gnBmpr2a domains,
953 depicted as interface score (REU) in relation to interface root mean square deviation (iRMSD)
954 in angstroms. Differences of the mean REU of out and mid LBD are calculated against inner
955 LBD. **(F)** Activin A-Cy5 surface binding to Halo-hBMPR2 and Halo-gnBmpr2a variants is
956 represented as relative fluorescence intensity per area. **(G)** pSMAD2/3 sensitive CAGA₁₂
957 Luciferase reporter activity of Halo-gnBmpr2a receptor variants as FI ± SD of relative
958 Luminescence Units (RLU). Statistical significance was calculated using two-way ANOVA and
959 Dunnett post-hoc test **(F)** relative to control **(G)** relative to hBMPR2 (*p < 0.05, **p < 0.01, ***p
960 < 0.001, ****p < 0.0001).

961

962

963

964




965

966 **Figure 4: Multimerized LBDs of TGFBR2 orthologs display varying degree of TGFβ1-**
 967 **interface conservation.** (A) Scheme of TGFBR2 LBD sequence identity comparison relative
 968 to respective inner LBD within each depicted animal. (B) Structure overview of hTGFβ1 with
 969 the LBD interface of hTGFBR2 obtained via Rosetta docking starting from an AlphaFold2-
 970 multimer prediction. Interaction is facilitated by c-terminus, finger motif 1 and 3 of receptor
 971 LBD. (C) Molecular surface of hTGFBR2 LBD showing the hTGFβ1 interface residues forming
 972 polar or hydrophobic contacts are colored in pink and gray, respectively (left). Sequence
 973 alignment of TGFBR2 LBDs of *Homo sapiens*, *Equus caballus*, *Gallus gallus*, *Xenopus laevis*,
 974 *Danio rerio*, *Cyprinus carpio* with TGFβ1 contact residues and critical backbone cysteins (teal)
 975 highlighted; interaction sites Finger 1, 3 and c-terminus are indicated with colored lines above
 976 (right). (D) Cartoon and stick representation of respective animal receptor LBD interaction with
 977 hTGFβ1 (c-terminus, finger motif 1 and 3) based on AlphaFold2-multimer models docked to
 978 hTGFβ1 using the lowest energy structure after performing a Rosetta docking protocol. PyMOL
 979 was used for image representation.

980


981




982

983 **Figure 5: TGFBR2 LBD duplications differently finetune signaling competence.** (A)
 984 Schematic representation of *in silico* binding analysis workflow using Rosetta docking.
 985 Alphafold (AF2 multimer) LBD-TGFβ1 complex structures are generated, followed by initial
 986 coordinate constrained relaxation to obtain optimized H-bonds. Docking of LBDs is then
 987 performed through RosettaScripts (n=2500). Interface score (REU) versus iRMSD plots
 988 identify the top 500 models with the lowest scores, indicating different ligand binding
 989 capabilities. (B) Illustration of LSBA for visualization and quantification of fluorescent hTGFβ1
 990 binding on COS-7 cells expressing respective Halo-tagged TGFBR2 receptor constructs. (C)
 991 Schematic representation of dual luciferase reporter gene assay used to assess TGFβ1

992 signaling activity through Halo-tagged TGFBR2 receptor orthologs. HEK293T cells are co-
 993 transfected with respective receptor variant, CAGA₁₂-firefly-Luc, and TK-renilla-Luc plasmids.
 994 Following TGFβ1 treatment for 24 hours, Firefly luciferase activity (indicative of TGFβ1
 995 pathway activation) and Renilla luciferase activity (normalization control) are measured. (D, G,
 996 J) *in silico* binding analysis via Rosetta docking of hTGFβ1 to inner (pink) and outer LBD (blue)
 997 of *D. rerio*, *E. caballus* and *G. gallus* depicted as interface score (REU) in relation to interface
 998 root mean square deviation (iRMSD) in angstroms. REU differences of LBDⁱⁿ and LBD^{out} are
 999 calculated by respective mean REU values of each LBD. (E, H, K) hTGFβ1-SiR-d12 surface
 1000 binding of *D. rerio*, *E. caballus* and *G. gallus* receptor variants represented as relative
 1001 fluorescence intensity per area. (F, I, L) pSMAD2/3 sensitive CAGA₁₂ Luciferase reporter
 1002 activity of *D. rerio*, *E. caballus* and *G. gallus* receptor variants as FI ± SD of RLU. Statistical
 1003 significance was calculated using two-way ANOVA and (F, H, I, K, L) Tukey's post-hoc test
 1004 within groups or (E, H) Dunnett post-hoc test relative to control (**p < 0.01, ***p < 0.001, ****p
 1005 < 0.0001).



1006
 1007 **Figure 6: Human TGFBR2 LBD duplication enhances ligand binding without affecting**
 1008 **downstream signaling.** (A) Representative confocal microscopy images of LSBA for
 1009 hTGFβ1-SiR-d12 stimulated COS-7 cells expressing hTGFBR2 or hTGFBR2-2LBD. Scale bar
 1010 \triangleq 20 μ m. (B) hTGFβ1-SiR-d12 surface binding of hTGFBR2 and hTGFBR2-2LBD represented
 1011 as relative fluorescence intensity per area. (C) pSMAD2/3 sensitive CAGA₁₂ Luciferase
 1012 reporter activity of hTGFBR2 and hTGFBR2-2LBD transfected HEK293 cells stimulated with
 1013 increasing hTGFβ1 concentrations depicted as FI \pm SD of relative Luminescence Units (RLU).
 1014 (D, left) Immunoblot analysis of HEK293T expressing hTGFBR2 or hTGFBR2-2LBD,
 1015 stimulated with 0.1 nM hTGFβ1 for 0 – 90 minutes and stained for Halo, pSMAD2 and GAPDH
 1016 as loading reference, (right) densitometric quantification of pSMAD2 levels relative to GAPDH
 1017 represented as F.I., n=3. (B, D) Statistical significance was calculated using two-way ANOVA
 1018 in between (B) or within (D) groups and Tukey's post-hoc test (*p < 0.05, ***p < 0.001, ****p <
 1019 0.0001). (E) Summary scheme comparing hTGFBR2 and hTGFBR2-2LBD ligand binding and
 1020 downstream pSMAD2/3 signaling. Increased ligand binding is not reflected on SMAD2/3
 1021 phosphorylation.



1022

1023

1024


1025

1026


Figure 7: Duplicated LBD *tgfr2* paralog exhibits limited signaling competence and cell type specific expression pattern in zebrafish. (A) Schematic comparison of human hTGFBR2, *Danio rerio* dTgfr2a and dTgfr2b receptor. **(B)** *In silico* binding analysis via Rosetta docking of hTGFβ1 to inner LBD of dTgfr2a (pink), dTgfr2b LBD (purple) and

1027 hTGFB2 (lavender) depicted as REU in relation to iRMSD in angstroms. REU differences are
1028 calculated by respective mean REU values of dTgfr2b to dTgfr2a or hTGFB2. **(C)** hTGFβ1-
1029 SiR-d12 surface binding of hTGFB2, dTgfr2a and dTgfr2b represented as relative
1030 fluorescence intensity per area. **(D)** pSmad2/3 sensitive CAGA₁₂ Luciferase reporter activity of
1031 dTgfr2b to dTgfr2a or hTGFB2 as FI ± SD of relative Luminescence Units (RLU).
1032 Significance was calculated using two-way ANOVA and Tukey's post-hoc test within groups
1033 (**p < 0.01, ****p < 0.0001). **(E)** UMAP representation of *D. rerio* transcriptome at 10 dpf,
1034 highlighting dTgfr2a and dTgfr2b positive cells (pink). **(F)** relative expression of dTgfr2a
1035 and dTgfr2b at 10 dpf in respective tissue; size of circle represents percentage of positive
1036 cells **(G)** relative expression of dTgfr2a and dTgfr2b in hematopoietic system and
1037 intermediate mesoderm at different developmental stages; size of circle represents percentage
1038 of positive cells **(H)** Venn diagrams of differentially expressed genes in dTgfr2a (pink) and
1039 dTgfr2b (purple) positive cells compared to double-negative controls at 1 and 10 dpf in
1040 hematopoietic system and intermediate mesoderm **(J)** Pseudo bulk expression of known
1041 SMAD2/3 target genes in dTgfr2a, dTgfr2b positive and double negative cells of the
1042 hematopoietic system at 1 dpf **(I)** Go term analysis of dTgfr2a positive cells at 1 and 10 dpf
1043 of the hematopoietic system and intermediate mesoderm. **(K)** Overexpression of dTgfr2a,
1044 dTgfr2a-LBDⁱⁿ, dTgfr2a-LBD^{out} and dTgfr2b in zebrafish embryos at 22 hpf. (left) Fraction
1045 of embryos showing normal, cyclopia or ventralized phenotypes after overexpression of
1046 indicated receptor constructs. (right) Representative brightfield images of embryos exhibiting
1047 indicated phenotypes. Purple arrowheads indicate fused eye structure in embryos with
1048 cyclopia phenotype. Pink arrowheads point to the reduction of head and neural tube structures
1049 in ventralized embryos. Scale bar = 100 μm.
1050
1051

A




B




1053

1054 **Supplemental Figure 1: LBD sequence identity comparison of ACVR1 and BMPR2**
 1055 **orthologs. (A)** ACVR1 LBD sequence identity matrix comparing all LBD ACVR1 variants of
 1056 indicated species. **(B)** BMPR2 LBD sequence identity matrix comparing all LBD BMPR2
 1057 variants of indicated species with each other.

A




B



1058

1059 **Supplemental Figure 2: LBD sequence identity comparison of TGFBR2 orthologs. (A)**
 1060 TGFBR2 LBD sequence identity matrix comparing all LBD TGFBR2 variants of human and
 1061 indicated ray finned fish species. (B) TGFBR2 LBD sequence identity matrix comparing all
 1062 LBD TGFBR2 variants of indicated jaw vertebrate as well as Cyprinoidei species.



1064


1065

1066

1067


Supplemental Figure 3: TGFBR2 LBD duplication independent of allotetraploid chromosomal evolution in *Cyprinus carpio* and *Xenopus laevis*. (A, top) Phylogenetic depiction of chromosomal evolution in the *Cyprinus* lineage, illustrating the allopolyploid origin

1068 of *Cyprinus carpio* (4n) from two diploid ancestors ("A" and "B"). Each ancestor contributed a
 1069 set of chromosomes (chr1A in blue, chr1B in red) leading to a tetraploid *C. carpio* with both
 1070 ancestral chromosome sets. *Danio rerio* is depicted with its diploid structure (2n), maintaining
 1071 a single chromosome set (chr1). **(Bottom)** Phylogenetic tree showing the relationship of
 1072 *tgfbr2a* gene variants between *C. carpio* and *D. rerio*. Structural variations in ligand-binding
 1073 domains are illustrated beside each gene. **(B, top)** Phylogenetic depiction of chromosomal
 1074 evolution in the *Xenopus* lineage, illustrating the allopolyploid origin of *Xenopus laevis* (4n)
 1075 from two diploid ancestors ("L" and "S"). Each ancestor contributed a set of chromosomes
 1076 (chr1L in blue, chr1S in red) leading to a tetraploid *X. laevis* with both ancestral chromosome
 1077 sets. *Xenopus tropicalis* is depicted with its diploid structure (2n), maintaining a single
 1078 chromosome set (chr1). **(Bottom)** Phylogenetic tree showing the relationship of *tgfbr2* gene
 1079 variants between *X. laevis* and *X. tropicalis*. Structural variations in ligand-binding
 1080 domains are illustrated beside each gene.
 1081



1082 **Supplemental Figure 4: Genetic architecture of duplicated LBDs of TGFβ receptor family**
 1083 **members. (A)** Schematic representation of receptor gene exon composition of *Acvr1*, *Acvr1L*,
 1084


1085 BMPR2, Bmpr2a, TGFBR2 and TGFBR2L. (B) Genomic organization of TGFBR2 intronic sites
 1086 flanking exons encoding in horse, chicken, and Tgfbra in zebrafish, including annotations size
 1087 and common repetitive elements.
 1088



1089





1090 **Supplemental Figure 5: Inner LBD conveys Activin A binding competence of LBD**
 1091 **multimerized BMPR2 orthologs. (A)** Molecular surface of hBMPR2 LBD showing the hActivin
 1092 A interface of a rosetta-docked AlphaFold2-multimer structure prediction. Residues forming
 1093 polar or hydrophobic contacts are colored in pink and gray, respectively (left). Sequence

1094 alignment of BMPR2 LBDs of *Homo Sapiens*, *G. petersii*, *G. niloticus* and *E. calabaricus* LBDs
1095 with hActivin A contact residues and critical backbone cysteins (teal) highlighted; interaction
1096 sites F3-loop and A-loop are indicated with colored lines (**right**). (**A, lower**) Cartoon and stick
1097 representation of respective animal receptor LBD interaction with hActivin A (A-loop) based on
1098 AlphaFold2-multimer models docked to hActivin A using Rosetta docking protocols. PyMOL
1099 was used for image representation. (**B**) Schematic representation of *in silico* binding analysis
1100 workflow using Rosetta docking. AlphaFold (AF2 multimer) LBD-Activin A complex structures
1101 are generated, followed by initial coordinate constrained relaxation to obtain optimized H-
1102 bonds. Docking of LBDs is then performed through RosettaScripts (n=2500). Interface score
1103 (REU) versus iRMSD plots identify the top 500 models with the lowest scores, indicating
1104 different ligand binding capabilities. (**C**) Illustration of LSBA for visualization and quantification
1105 of fluorescent hActivin A binding on COS-7 cells expressing respective Halo-tagged BMPR2
1106 receptor constructs. (**D**) Schematic representation of dual luciferase reporter gene assay used
1107 to assess Activin A signaling activity through Halo-tagged BMPR2 receptor orthologs.
1108 HEK293T cells are co-transfected with respective receptor variant, CAGA₁₂-firefly-Luc, and
1109 TK-renilla-Luc plasmids. Following Activin A treatment for 24 hours, Firefly luciferase activity
1110 (indicative of Activin A pathway activation) and Renilla luciferase activity (normalization control)
1111 are measured. *In silico* binding analysis of (**E**) *G. petersii* (**F**) *P. kingsleyae* (**G**) *E. calabaricus*
1112 Activin A interactions with its respective single Bmpr2a domains obtained via Rosetta Docking,
1113 depicted as interface score (REU) in relation to interface root mean square deviation (iRMSD)
1114 in angstroms. (**right**) Illustration of respective animal BMPR2a 3 LBD receptor domain
1115 structure as reference, highlighting the inner (pink), middle (green) and outer (blue) ligand
1116 binding domain. REU differences of out and mid LBD mean are calculated against inner LBD
1117 mean value.
1118
1119



1120
1121
1122
1123
1124
1125


Supplemental Figure 6: Representative LSBA images of Activin A bound to gnBmpr2a variants. Representative confocal microscopy images of LSBA for unstimulated and hActivinA-Cy5 stimulated COS-7 cells expressing *Gnathonemus petersii* receptor variants (gnBmpr2a (3LBD), gnBmpr2a-LBD^{mid-in}, gnBmpr2a-LBDⁱⁿ, gnBmpr2a-LBD^{mid}, gnBmpr2a-LBD^{out}) or hBMPR2 or untransfected control. Scale bar \cong 20 μ m.




1136

1137 **Supplemental Figure 8: Evolutionary divergence of duplicated LBD domains relative to**
 1138 **species divergence times.** Each panel shows the relationship between amino-acid distance
 1139 and species divergence time for duplicated LBDs of TGFBR2/Tgfbr2a in four focal species:

1140 horse, chicken, salmon, and zebrafish. Pink circles represent pairwise comparisons between
 1141 the inner LBD of the focal species and the orthologous inner LBD of other species in the same
 1142 clade. The gray line depicts the clade-specific molecular clock, obtained by weighted linear
 1143 regression of amino-acid distance against species divergence time; the resulting substitution
 1144 rate (\bar{r}), expressed as substitutions per site per million years, is shown in each panel. The blue
 1145 star marks the observed amino-acid divergence between the two duplicated LBD copies within
 1146 the focal species, and the duplication-specific evolutionary rate (r_{dup}) is reported in each
 1147 panel.



1148 **Supplemental Figure 9: Functional implications of LBD multiplication in TGFBR2**
 1149 **orthologs of *Cyprinus carpio* and *Xenopus laevis*.** (A, D) *in silico* binding analysis via
 1150 Rosetta docking of hTGFβ1 to inner (pink) and outer LBD (blue) of *C. carpio*, *X. laevis* depicted
 1151 as interface score (REU) in relation to interface root mean square deviation (iRMSD) in
 1152 angstroms. REU differences of in and out are calculated by respective mean REU values of
 1153 each LBD. (B, E) hTGFβ1-SiR-d12 surface binding of *C. carpio*, *X. laevis* receptor variants
 1154 represented as relative fluorescence intensity per area. (C, F,) pSmad2/3 sensitive CAGA₁₂
 1155 Luciferase reporter activity of *C. carpio*, *X. laevis* receptor variants as FI ± SD of relative
 1156 Luminescence Units (RLU). Statistical significance was calculated using two-way ANOVA and
 1157 (B,E) Dunnett post-hoc test relative to control (B) or xITgfr2.L (E) or using two-way ANOVA
 1158 and (C,F) Tukey's post-hoc test within groups (*p < 0.05, **p < 0.01, ***p < 0.001, ****p <
 1159 0.0001).




1161
 1162 **Supplemental Figure 10: *In silico* binding analysis of TGFBR2 orthologs with respective**
 1163 **animal TGFβ1.** *In silico* binding analysis via Rosetta docking and illustration of respective
 1164 animal TGFBR2 LBD receptor domain structure as color reference of (A) *Danio rerio* (B) *Equus*
 1165 *callabus* (C) *Gallus gallus* (D) *Cyprinus carpio* (E) *Xenopus laevis* TGFβ1 interactions with its
 1166 respective single TGFBR2/Tgfr2a/Tgfr2.L domains, depicted as interface score (REU) in
 1167 relation to interface root mean square deviation (iRMSD) in angstroms. REU differences of out
 1168 and mid LBD mean are calculated against inner LBD mean value.
 1169

1170

1171


1172



1173


1174 **Supplemental Figure 11: *In silico* binding analysis of ray-finned fish TGFBR2 orthologs**
 1175 **with human and respective animal TGFβ1.** Illustration of respective animal TGFBR2 LBD
 1176 receptor domain structure as color reference and Rosetta docking via *in silico* binding analysis
 1177 of (A) *Clupea harengus* (B) *Esox lucius* (C) *Salmo salar* (D) *Salvelinus namaycush* TGFβ1 and
 1178 hTGFβ1 interactions with respective single Tgfbr2a domains, depicted as interface score

1179 (REU) in relation to interface root mean square deviation (iRMSD) in angstroms. REU
 1180 differences of out and mid LBD mean are calculated against inner LBD mean value.
 1181




1182

1183 **Supplemental Figure 12: Representative LSBA images of TGF β 1 bound to dTgfr2a/b**
 1184 **variants.** Representative confocal microscopy images of LSBA for unstimulated and hTGF β 1-
 1185 SiR-d12 stimulated COS-7 cells expressing human BMPR2 or *danio rerio* variants (dTgfr2b,
 1186 dTgfr2a (2LBD), dTgfr2a-LBDⁱⁿ, dTgfr2a-LBD^{out}) or untransfected control. Scale bar \cong 20
 1187 μ m.



1188


1189 **Supplemental Figure 13: Representative LSBA images of TGFβ1 bound to cTgfr2a**
 1190 **variants.** Representative confocal microscopy images of LSBA for unstimulated and hTGFβ1-
 1191 SiR-d12 stimulated COS-7 cells expressing human TGFB2 or *Cyprinus carpio* variants
 1192 (cTgfr2a (2LBD), cTgfr2a-LBDⁱⁿ, cTgfr2a-LBD^{out}) or untransfected control. Scale bar ≅ 20
 1193 μm.



1194


1195 **Supplemental Figure 14: Representative LSBA images of TGFβ1 bound to xITgfr2.L**
 1196 **variants.** Representative confocal microscopy images of LSBA for unstimulated and hTGFβ1-
 1197 SiR-d12 stimulated COS-7 cells expressing human TGFBR2 or *Xenopus laevis* variants
 1198 (xITgfr2.L (3LBD), xITgfr2.L-LBD^{mid-in}, xITgfr2.L-LBDⁱⁿ, xITgfr2.L-LBD^{out}) or untransfected
 1199 control. Scale bar ≅ 20 μm.

1200



1201
 1202 **Supplemental Figure 15: Representative LSBA images of TGFβ1 bound to eTGFBR2**
 1203 **variants.** Representative confocal microscopy images of LSBA for unstimulated and hTGFβ1-
 1204 SiR-d12 stimulated COS-7 cells expressing *Equus caballus* variants (eTGFBR2 (2LDB),
 1205 eTGFBR2-LBDⁱⁿ, eTGFBR2-LBD^{out}) and human TGFBR2 or untransfected control. Scale bar
 1206 ≅ 20 μm.
 1207

1208
 1209
 1210




1211

1212 **Supplemental Figure 16: Representative LSBA images of TGFβ1 bound to gTGFB2**
 1213 **variants.** Representative confocal microscopy images of LSBA for unstimulated and hTGFβ1-
 1214 SiR-d12 stimulated COS-7 cells expressing human TGFB2 and *Gallus gallus* variants
 1215 (gTGFB2 (2LBD), gTGFB2-LBDⁱⁿ, gTGFB2-LBD^{out}) and human TGFB2 or untransfected
 1216 control. Scale bar ≅ 20 μm.


1217

1218




1220

1221 **Supplemental Figure 17: Representative LSBA images of TGF β 1 bound to hTGFB2**
 1222 **variants.** Representative confocal microscopy images of LSBA for unstimulated COS-7 cells
 1223 expressing hTGFB2 or hTGFB2-2LBD or untransfected control and hTGFB β 1-SiR-d12
 1224 stimulated untransfected cells. Scale bar \triangleq 20 μ m.
 1225




1226

1227 **Supplemental Figure 18: Alternative splice variants of TGFBR2 in horse and chicken.**
 1228 (A, top) Exon organization of horse eTGFBR2 and chicken gTGFBR2 with DNA/protein
 1229 similarity percentages between corresponding exons. (bottom) Illustration of alternative splice
 1230 variants, showing different combinations of exons leading to 2LBD, LBD_{out}, LBD_{in} receptor
 1231 variants. (B) Summary of relative usage 2a/2b usage across 14 horse tissues. Tissues are
 1232 indicated on the left (reproduction, blood vessels, lung, heart). Tissues used for Sashimi plots
 1233 are highlighted. (C,D) Sashimi plot of the E1 to E5 region of horse (left) and chicken (right)
 1234 TGFBR2. Exon coverage is shown on the left. Junctions are indicated by lines, junctions not
 1235 supported by unique reads are shown as dotted lines. Next to each junction the black number
 1236 shows all reads mapped to this junction, the red number reports unique reads only.



1237
1238
1239
1240
1241

Supplemental Figure 19: Coinjected membrane bound PMT-mEGFP expression control in zebrafish embryos. (A) Expression of coinjected PMT-mEGFP allows selection of dTgfr2 overexpression embryos. Scale bar = 100 μ m.



1242

1243 **Supplemental Figure 20: Western blot expression controls of Halo-tagged receptor**
 1244 **constructs.** Western blot analysis of HEK293T cell transiently expressing (A) *Gnathonemus*
 1245 *petersii* receptor variants (gBmpr2a (3LBD), gBmpr2a-LBD^{midin}, gBmpr2a-LBDⁱⁿ, gBmpr2a-
 1246 **LBD^{mid}, gBmpr2a-LBD^{out}) or hBMPr2 and hACVR2B as size reference (B) *Danio rerio* receptor**
 1247 **variants (dTgfr2b, dTgfr2a (2LBD), dTgfr2a-LBDⁱⁿ, dTgfr2a-LBD^{out}) or hTGfBR2 as size**
 1248 **reference (C) *Equus caballus* variants (eTGfBR2 (2LBD), eTGfBR2-LBDⁱⁿ, eTGfBR2-LBD^{out})**
 1249 **and hTGfBR2 as size reference (D) *Gallus gallus* variants (gTGfBR2 (2LBD), gTGfBR2-**
 1250 **LBDⁱⁿ, gTGfBR2-LBD^{out}) and hTGfBR2 as size reference (E) *Cyprinus carpio* variants**
 1251 **(cTgfr2a (2LBD), cTgfr2a-LBDⁱⁿ, cTgfr2a-LBD^{out}) or hTGfBR2 as size reference (F)**

1252 *Xenopus laevis* variants (xITgfr2.L (3LBD), xITgfr2.L-LBD^{mid-in}, xITgfr2.L-LBDⁱⁿ, xITgfr2.L-
 1253 LBD^{out}) or hTGFR2 as size reference (**G**) hTGFR2 and hTGFR2-2LBD. GAPDH was used
 1254 as loading reference.

1255
 1256

Table 1: N-terminally tagged HaloTag expression constructs

Plasmid Name	Description	Backbone	Resistance
eTGFR2-Halo	full length eTGFR2 with N-terminal HaloTag	pcDNA3.1	Ampicillin
eTGFR2 LBD ⁱⁿ -Halo	eTGFR2 LBD ⁱⁿ variant with N-terminal HaloTag	pcDNA3.1	Ampicillin
eTGFR2 LBD ^{out} -Halo	eTGFR2 LBD ^{out} variant with N-terminal HaloTag	pcDNA3.1	Ampicillin
dTgfr2a-Halo	full length dTgfr2a with N-terminal HaloTag	pcDNA3.1	Ampicillin
dTgfr2a LBD ⁱⁿ -Halo	dTgfr2a LBD ⁱⁿ variant with N-terminal HaloTag	pcDNA3.1	Ampicillin
dTgfr2a LBD ^{out} -Halo	dTgfr2a LBD ^{out} variant with N-terminal HaloTag	pcDNA3.1	Ampicillin
dTgfr2b-Halo	dTgfr2b with N-terminal HaloTag	pcDNA3.1	Ampicillin
cTgfr2a-Halo	full length cTgfr2a with N-terminal HaloTag	pcDNA3.1	Ampicillin
cTgfr2a LBD ⁱⁿ -Halo	cTgfr2a LBD ⁱⁿ variant with N-terminal HaloTag	pcDNA3.1	Ampicillin
cTgfr2a LBD ^{out} -Halo	cTgfr2a LBD ^{out} variant with N-terminal HaloTag	pcDNA3.1	Ampicillin
gnBmpr2a-Halo	full length gnBmpr2a with N-terminal HaloTag	pcDNA3.1	Ampicillin
gnBmpr2a LBD ⁱⁿ -Halo	gnBmpr2a LBD ⁱⁿ variant with N-terminal HaloTag	pcDNA3.1	Ampicillin
gnBmpr2a LBD ^{mid-in} -Halo	gnBmpr2a LBD ^{mid-in} variant with N-terminal HaloTag	pcDNA3.1	Ampicillin
gnBmpr2a LBD ^{out} -Halo	gnBmpr2a LBD ^{out} variant with N-terminal HaloTag	pcDNA3.1	Ampicillin
gnBmpr2a LBD ^{mid} -Halo	gnBmpr2a LBD ^{mid} variant with N-terminal HaloTag	pcDNA3.1	Ampicillin
gTGFR2-Halo	full length gTGFR2 with N-terminal HaloTag	pcDNA3.1	Ampicillin
gTGFR2 LBD ⁱⁿ -Halo	gTGFR2 LBD ⁱⁿ -Halo variant with N-terminal HaloTag	pcDNA3.1	Ampicillin
gTGFR2 LBD ^{out} -Halo	gTGFR2 LBD ⁱⁿ -Halo variant with N-terminal HaloTag	pcDNA3.1	Ampicillin
xITgfr2.L – blunt end	full length xITgfr2.L in blunt end vector	pCR TM -Blunt-vector	Ampicillin
xITgfr2.L	full length xITgfr2.L with N-terminal HaloTag	pcDNA3.1	Ampicillin
xITgfr2.L LBD ⁱⁿ	xITgfr2.L LBD ⁱⁿ variant with N-terminal HaloTag	pcDNA3.1	Ampicillin
xITgfr2.L LBD ^{mid-in}	xITgfr2.L LBD ^{mid-in} variant with N-terminal HaloTag	pcDNA3.1	Ampicillin
pcs2+PMT-mEGFP	Membrane bound mEGFP: Gift from Dr. Thorsten Wohland (Balasubramanian et. al, 2022, RRID: Addgene_203777), subcloned into pCS2+ backbone for capped mRNA synthesis (Le et al., 2025)	pcs2+	Ampicillin
xITgfr2.L LBD ^{out}	xITgfr2.L LBD ^{out} variant with N-terminal	pcDNA3.1	Ampicillin

1257
 1258
 1259
 1260

Table 2: Oligonucleotides used for molecular cloning of LBD-Halo constructs

Name	Oligonucleotide-sequence (5'-3')	
	for	rev
eTGfBR2	CATAATTTTCAGTGAAAACCCCGACTTGC TTTTAGTTATCTTTCAAG	ATAACTAAAAGCAAGTCGGGGTTTTCACTGA AAATTATGTGGTCGTTGC
eTGfBR2 LBD ⁱⁿ	GCACTGCGGCTGCTGGATCCGCAGAAAT CGGTACTGGCTTTCCATTC	ACTAAAAGCAAGTCGGGGTTTTCACTGAAAA TTATGTGGTCG
eTGfBR2 LBD ^{out}	AACCCCGACTTGCTTTTAGTTATCTTTCA AGTGACAGGGG	GGATCCAGCAGCCGCAGTGCTGACCAGCAG GATGGTCCATGG
dTgfr2a	GGTGGAGAATTCCGCATCTGCAGCTCCT GTAAGCCTCATCCAGTCAACTG	GCTCGAGCGGCCGCCTACATCTCTTGTATCC CAGAATCC
dTgfr2a LBD ⁱⁿ	GGTGGAGAATTCTTGTGCGAAGACAAACT CCAGCAGC	GCTCGAGCGGCCGCCTACATCTCTTGTATCC CAGAATCC
dTgfr2a LBD ^{out}	GATTTGAAACAATATCCAGGGGTTTCAG	CAATTTCTCCTCCTCAGTGAGTTTG
dTgfr2b	GGTGGAGAATTCCGCGGAGTCGATGGA AATAATCC	GCTCGAGCGGCCGCTCATTGTGCTCGCTCA CGCTCAGC
cTgfr2a	GGTGGAGAATTCAATCCACACAGTGTGT GTAAGTCATGTGACC	GCTCGAGCGGCCGCCTATTTCTCATCATTCC CAGAATCC
cTgfr2a LBD ⁱⁿ	GATAACGACACCAAGTTAGTTATATTG	ATTGAATTCTCCACCTCCACCTCCGC
cTgfr2a LBD ^{out}	GTTTCGTCTCCTCCAGGAGACTATAAG	GAGTCTGAACCCTCCTTTTCGTTTC
gnBmpr2a	GGTGGAGAATTCCGCCAAGCGGAAGAC CGCGTGTGC	GCTCGAGCGGCCGCCTAATTAACGGTAGGT GACACG
gnBmpr2a ⁱⁿ	GGTGGAGAATTCCGCACCTAATGAAGAAA GGGAATGC	GCTCGAGCGGCCGCCTAATTAACGGTAGGT GACACG
gnBmpr2a ^{mid-in}	GGTGGAGAATTCCGCCGAAAGAGACGAAT TGC	GCTCGAGCGGCCGCCTAATTAACGGTAGGT GACACG
gnBmpr2a ^{out} (Gibson)	Backbone: CCGCTGTTCCGGTCCAACATCCACTCAAC CCCTCTATCCAC LBD^{out}: GAGGTGGAGGTGGAGAATTCGCCAAG CGGAAGACCGCGTG	Backbone: GAATTCTCCACCTCCACCTCCGCCGGAATC TCGAGCGTGC LBD^{out}: GATGTTGGACCGAACAGCGGAAAATCTTCGG TGAAATTAAGATTAC
gnBmpr2a ^{mid} (Gibson)	Backbone: CCGCTGTTCCGGTCCAACATCCACTCAAC CCCTCTATCCAC LBD^{mid}: GAGGTGGAGGTGGAGAATTCGCCGAAA GAGACGAATTGCAATGC	Backbone: GAATTCTCCACCTCCACCTCCGCCGGAATC TCGAGCGTGC LBD^{mid}: GATGTTGGACCGAACAGCGGAGACAGATCG GTGAAGTTTAC
gTGfBR2 & gTGfBR2 LBD ^{out}	GGTGGAGAATTCAGAAGCAAGGAAAATG GACTGC	GCTCGAGCGGCCGCCTACTTGGCGGTGGTC ACGGAGC
gTGfBR2, gTGfBR2- LBD ^{out} (Gibson)	Backbone: GGCATCCAGATGGTGTGCGAGACCCTTA TCGAGTGCTGGG Exon 6/7 Del: TGCCATTGAACTGGACATTGTTGTTGG CAAAGGAAGGTTTGCTGAAGTG	Backbone: GGCATCCAGATGGTGTGCGAGACCCTTATCG AGTGCTGGG Exon 6/7 Del: TCGCACACCATCTGGATGCCCTGATGGTTAA GCCAGGAGCTGG
gTGfBR2 LBD ⁱⁿ	CCCCATAAGCCAGAGGAGAAAGATGAAA TTTCC	CCTAAATCTGTTTGCAGAAAAATAAG
xITgfr2.L – blunt end	GGTACCTCCACCAAGGGCGAATTCTGC	ACATTTCCCTTATACCTGGGTTCTAGTC
xITgfr2.L LBD ⁱⁿ (Gibson)	Backbone: GATGACCCATCAAAGACATACTTGTGA AAGCTCTTCTCATC LBDⁱⁿ: GAGGTGGAGGTGGAGAATTCAGTATAAA GGATTGTGC	Backbone: GAATTCTCCACCTCCACCTCCGCCGGAATC TCGAGCGTGCAGACCC LBDⁱⁿ: ATGTCTTTTGTGGTTCATCTTTAGAAAAAA CAAGTTTTTATTACACAGC
xITgfr2.L LBD ^{mid-in} (Gibson)	Backbone: GATGACCCATCAAAGACATACTTGTGA AAGCTCTTCTCATC	Backbone: GAATTCTCCACCTCCACCTCCGCCGGAATC TCGAGCGTGCAGACCC

	LBD^{mid-in}: CCGGCGGAGGTGGAGGTGGAGAATTCC CTGTTTCATGTACCTGTTGTATGC	LBD^{mid-in}: ATGCTTTTGATGGGTCATCTTTAGAAAAAA CAAGTTTTTCATTACACAGC
xITgbr2.L LBD ^{out} (Gibson)	Backbone: GATGACCCATCAAAGACATACTTGTGA AAGCTCTTCTCATC LBD^{out}: GAGGTGGAGGTGGAGAATTCTACCTGG GTTCTAGTCGTTTATGC	Backbone: GAATTCTCCACCTCCACCTCCGCCGAAATC TCGAGCGTCGACAGCC LBD^{out}: ATGCTTTTGATGGGTCATCATCTGTGAAGACT ATTTGTTTCATTGC

1262

1263